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ABSTRACT 
 
A major challenge in cancer treatment is predicting the clinical response to anti-cancer drugs on 
a personalized basis. The success of such a task largely depends on the ability to develop 
computational resources that integrate big “omic” data into effective drug-response models. 
Machine learning is both an expanding and an evolving computational field that holds promise to 
cover such needs. Here we provide a focused overview of: 1) the various supervised and 
unsupervised algorithms used specifically in drug response prediction applications, 2) the 
strategies employed to develop these algorithms into applicable models, 3) data resources that 
are fed into these frameworks and 4) pitfalls and challenges to maximize model performance. In 
this context we also describe a novel in silico screening process, based on Association Rule 
Mining, for identifying genes as candidate drivers of drug response and compare it with relevant 
data mining frameworks, for which we generated a web application freely available at: 
https://compbio.nyumc.org/drugs/. This pipeline explores with high efficiency large sample-
spaces, while is able to detect low frequency events and evaluate statistical significance even in 
the multidimensional space, presenting the results in the form of easily interpretable rules. We 
conclude with future prospects and challenges of applying machine learning based drug response 
prediction in precision medicine. 
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Abbreviations list 
Molecular terms 
ARHGDIB: Rho GDP dissociation inhibitor beta 
BCL2: BCL2 Apoptosis Regulator 
BRCA1: Breast cancer type 1 Susceptibility Protein 
BRAF: B-Raf proto-oncogene, Serine/Threonine Kinase 
CCND3: Cyclin D3 
CD151: Tetraspanin-24 
CDC6: Cell cycle division 6 
CDKN2A: Cyclin dependent kinase inhibitor 2A 
CTCF: 11-zinc finger protein or CCCTC-binding factor 
DDR: DNA damage response 
EGFR: Epidermal growth factor receptor 
EMT: Epithelial to mesenchymal transition 
ERK: Extracellular regulated kinase 
FLT3: Fms related tyrosine kinase 3 
GHRH: Growth hormone-releasing hormone 
GMIP: GEM interacting protein 
ID1: Inhibitor of DNA binding 1 
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KRAS: Kirsten rat sarcoma proto-oncogene 
LYL1: Lymphoblastic leukemia associated hematopoiesis regulator 1 
MAGI3: Membrane-Associated Guanylate Kinase 3 
MAPK: Mitogen-activated protein kinase 
MAP2K3: Mitogen-activated protein kinase kinase 3 
MDM2: Mouse double minute 2 
MDR1: Multidrug resistance 1 
MEK: Mitogen-activated protein kinase kinase 
MLL2: KMT2D - Histone-Lysine N-Methyltransferase MLL2 
mTOR: mechanistic target of rapamycin kinase 
MYC: MYC Proto-Oncogene, BHLH Transcription Factor 
NPTN: Neuroplastin 
NQO1: NAD(P)H dehydrogenase 1 
NSCLC: Non-small cell lung cancer 
PARP: Poly(ADP-ribose) polymerase 
PDIA3: ERp57/PDIA3: Protein disulfide isomerase family 
PI3K: Phosphoinositide 3-kinase 
PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase 
POF1B: Premature Ovarian Failure Protein 1B 
PTEN: Phosphatase and tensin homolog 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
REV7: MAD2L2 - Mitotic Arrest Deficient 2 Like 2 
SAMSN1: SAM domain, SH3 domain and nuclear localization signals 1 
SCLC: Small cell lung cancer 
SHLD1-3: Shieldin complex subunit 1-3 
SMAD3: Mothers Against Decapentaplegic Homolog 3 
TKI: Tyrosine Kinase Inhibitor 
TP53: Tumor Protein p53 
ZCCHC7: Zinc finger CCHC-type containing 7 
ZNF22: Zinc finger protein 22 
Statistical, machine learning and cell lines databases terms 
ACC: Accuracy 
ANOVA: Analysis of variance 
ARM: Association Rule Mining 
AUC: Area under the ROC curve 
BATTLE: Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination 
BEMKL: Bayesian efficient multiple kernel learning 
CCLE: Cancer Cell Line Encyclopedia 
CCLP: Cosmic Cell Line Project 
CNV: Copy Number Variations 
CTRP: Cancer Therapeutic Response Portal 
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cwKBMF: component-wise Kernelized Bayesian matrix factorization 
DLNN: Deep Learning Neural Networks 
DREAM: Dialogue on Reverse Engineering Assessment and Methods 
FDR: False Discovery Rate 
FN: False Negative 
FNR: False Negative Rate 
FOR: False Omission Rate 
FP: False Positive 
FPR: False positive rate 
GBMS: Gradient Boosting machines 
GDSC: Genomics of Drug Sensitivity in Cancer 
KF-CV: k-fold cross-validations 
KNN: K-nearest neighbors 
LOBICO: Logic Optimization for Binary Input to Continuous Output 
MCDA: Multi-criteria decision analysis 
MKL: Multiple Kernel Learning 
Mut: Mutations 
NCI-60: National Cancer Institute drug screening panel 
NPV: Negative Predictive Value 
PCA: Principal Component Analysis 
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PPV: Positive Predictive Value 
SNE: Stochastic Neighbor Embeding 
RMSE: Root Mean Square Error 
STREAM: Scalable-Time Ridge Estimator by Averaging of Models 
SVM: Support Vector Machines 
TCGA: The Cancer Genome Atlas 
TCPA: The Cancer Proteome Atlas 
TN: True Negative 
TP: True Positive 
TNR: True Negative Rate 
TPR: True Positive Rate 
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1. Introduction: Τhe urge for “big data” analyzers in precision medicine 
    Predicting the clinical response to therapeutic agents is a major challenge in cancer treatment. 
Traditional features such as, histopathological characteristics of tumors, although always useful, 
have reached their limit and are unable to solely guide “precise” therapeutic solutions.   
The advent of multiple high-throughput platforms producing “οmics” data has provided to the 
biomedical community, over the last decade, a huge molecular repository of data (big data) – for 
terms in bold see Table 1 for machine learning terminology that is continuously expanding and promises to pave 
the way to precision medicine approaches. Such information merged with detailed clinical 
records, including response to therapy, will enable scientists to dissect the molecular events that 
are known to drive carcinogenesis and alter major downstream processes, such as gene 
expression (Halazonetis et al., 2008; Negrini et al., 2010; Galanos et al., 2018; Alexandrov et 
al., 2013; Zhang et al., 2016). Ultimately, molecular disease signatures are anticipated to be 
delivered and matched with the most effective therapeutic interventions.  
     The only efficient means to exploit the multi-dimensionality of the generated large data sets 
and to achieve the goal of predicting drug responses are computational technologies (Figure 1). 
Presently, in silico tools have propelled a widespread effort to effectively translate the growing 
wealth of high-throughput profiling data into clinically meaningful, personalised treatment 
strategies required by precision medicine (van't Veer and Bernards, 2008; Ali and Aittokallio, 
2019; Azuaje F, 2017). However, the computational prediction of drug responses in cancer 
involves significant research challenges and questions including: i) which data set 
should be selected, ii) which computational setting is suitable for application, iii) are the 
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produced models valid to all types of cancer or a specific one, and iv) how is the 
efficacy of the models evaluated and validated. Herein, we address these critical 
questions by: i) presenting and discussing current trends in machine learning and data 
mining methodologies related to drug response (Table 1, Figures 1, 2) and ii) 
suggesting means to increase their competence. Finally, we present a novel in silico 
screening process that is based on an unsupervised data mining method called 
Association Rule Mining– for terms in bold and italics see Table 2 for description of computational algorithms 
(ARM)*-see Abbreviations table that is capable of generating simple rules linking a specific 
gene(s) status with drug response.   
 
2. The tools it takes to grasp valuable clinical information  
2a. The overall in silico strategy: The standard scheme to develop a computational model for 
predicting biological outcomes includes three key steps (Figures 1-3): i) opting the data set, ii) 
selecting the algorithm and training it to develop a prediction model, and iii) testing it in 
unseen data sets (Figure 3, and for terminology see Table 1). In the first step the desired data 
set(s) is selected and pre-processed. The latter includes feature selection, normalization, when 
more than one data set is combined, and filtering of noise or irrelevant information. Choosing 
the proper features is a pivotal stage for algorithms to be effective in classification, regression 
and pattern recognition (see paragraph 2b). The second step involves the training phase that 
aims in building the fittest model for drug response prediction. There is a wide range of 
computational approaches that are used to process the data sets (Figures 1, 2). A list and a brief 
description of the most commonly applied ones is presented in Table 2. Basically, they are 
divided into supervised and unsupervised learning techniques (Figure 1, Table 2). Although 
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the former methods are the most widely used, it is notable that the latter ones can provide the 
ground for generating prediction models, as they carry out fundamental tasks, such as 
clustering and sample stratification data, prior to the implementation of supervised learning 
(Zhao et al., 2014; Azuaje F, 2017; Byers et al., 2013; Moghaddas Gholami et al., 2013), as 
well as provide critical insights and knowledge extraction. Actually, unsupervised clustering 
represented the basis for traditional analytical strategies trying to identify efficient treatments in 
distinct patient sub-clusters (Hoadley et al., 2014, Campbell et al., 2017), or alternatively 
starting from treatment response clustering and then moving into the molecular context that 
could explain drug behaviour (Pemovska et al. 2013; Tyner et al. 2013; Frismantas et al. 
2017; Andersson et al. 2018). The third step, also termed independent evaluation, is the 
decisive one as it will test if the candidate model, after training, can accurately predict response 
on unseen settings either experimental ones such as, cell lines, xenografts or animal models, or 
preferably in clinical samples.  
      In the following subsections each step will be discussed in more detail, including 
comparison of methodologies, pointing out potential weak spots that need to be improved in the 
future to maximize the predictive power of these artificial intelligence-based frameworks 
(Figures 1, 2).  
2b. Data resources and categories of input data: A proficient prediction model largely depends 
on the “quantity and quality” of the input data. With the term “quality” we refer mainly to 
normalization and the source of the data. Normalization is an essential process when different 
data sets are merged ensuring that bias during the analysis is avoided, and includes operations 
such as, matching, batch effect removal and data imputation (when data are missing in one 
or more of the data sets) (Hastie et al., 2001). Ideally, to develop promising drug prediction 
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models the origin of the data should be clinical derived material and to a large extent success 
has been hindered by the lack of such reliable sources. Nevertheless, despite the fact that 
individual cancer cell lines do not reflect the complexity of clinical cancer tissues with fidelity 
(Weinstein, 2012), when compiled in large panels, it appears that they are able to recapitulate 
the genomic diversity of human cancers (Iorio et al., 2016). These panels can be readily utilised 
as platforms upon which expert systems for the prediction of pharmacological response may be 
developed. Currently the most significant resources of input data for drug response studies are 
publically available cell line repositories that include dose response data for a large number of 
compounds. Particularly, the Cancer Cell Line Encyclopedia (CCLE)*, the Genomics of Drug 
Sensitivity in Cancer (GDSC)* project and the National Cancer Institute drug screening panel 
(NCI-60)* are the most widely used panels as they offer: i) baseline data (i.e molecular features 
from untreated samples) containing mutation, gene copy number, gene expression, and in the 
case of NCI-60 protein data information, and ii) various measurements of drug sensitivity in a 
large number of compounds (Table 3). Notably, NCI-60 has information for more than 1500 
compounds, but in only 59 cell lines from 9 tissues, which makes CCLE and GDSC much more 
popular as they have data for more that 1000 cell lines derived from 15 and 36 cancer types, 
respectively (Table 3). Finally another unique resource that needs to be mentioned is the 
AstraZeneca-Sanger DREAM* challenge drug-synergy dataset that contains 910 pairwise 
combinations of 118 drugs tested on 85 cell lines whose ‘omic’ profiling is available through 
GDSC (Table 3).   
     Another important issue in developing an efficient prediction model is the type of data used 
(feature selection). In general, in most models the input information consists mainly of single-
nucleotide mutations, copy number variations, gene expression and of course the performance 
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to the therapeutic agent(s)/scheme (Jang et al., 2014; Costello et al., 2014; Daemen et al., 
2013; Geeleher et al., 2014). Comparative analyses until now have demonstrated that in most 
cases gene expression determines the most powerful predictive features. On the other hand, 
integrated approaches, combining various “omic” modalities only marginally affect drug 
response (Jang et al., 2014; Costello et al., 2014). However, there are exceptions in this 
general tendency suggesting that more studies are required including combination of genomic, 
transcriptomic, epigenomic and proteomic profiles as data types (Moghaddas Gholami et a., 
2013; Corte´s-Ciriano et al., 2016; Mendenet et al., 2013; Fey et al., 2015; Zhang et al., 
2015; Niepel et al., 2013). Recently, simulations of signalling pathway activity has become the 
focus of investigation in prognostic models providing promising results (Fey et al., 2015); thus 
exemplifying that apart from developing novel computational methodologies, blending of 
different data types could help overcome study constrains.  
2c. Computational techniques and selection of prediction models: The machine learning  
algorithms used to building drug response prediction models are mainly based on 
supervised learning techniques, although, as mentioned above, in many cases 
unsupervised methods provide the basis for the former (Moghaddas Gholami et a., 2013; 
Byers et al., 2013; Nicolau et al., 2011) (Table 2, Figures 1, 2).The methods 
presented in Table 2 can be broadly grouped in supervised and unsupervised learning 
methods. Linear, Ridge, Lasso and Elastic Net regression are examples of linear 
supervised learning, while kernel-based support vector machines, decision-
trees/random-forests and artificial neural networks (shallow and deep) are examples 
of non-linear supervised learning (Table 2). Principle Components Analysis (PCA)* 
and t-SNE* (Table 2) are characteristic examples of linear and non-linear 
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dimensionality reduction techniques, respectively, which fall under unsupervised 
learning, along with clustering methodologies such as k-means, hierarchical and k-
nearest-neighbor clustering (Table 2).  
    Although, all methods have pros and cons (Table 2) and no single approach can 
consistently surpass others on different settings, it appears that regression models tend 
to perform better when applied in diverse data sets (Stransky et al., 2015; Jang et al., 
2014). Nonetheless, the ascertainment that no “true winner” exists has led to the development 
of different model building strategies. Ensembling different techniques and learning 
frameworks have emerged as a promising approach (a process termed ensemble learning – see 
Table 2). A characteristic example is the DREAM7 Challenge setup which utilized the Bayesian 
efficient multiple kernel learning (BEMKL)* method that leveraged four machine-learning 
principles: i) kernelized regression, ii) multi-view learning, iii) multi-task learning, and iv) 
Bayesian inference (Costello et al., 2014). Particularly, Kernel regression gave mainly the 
advantage to capture non-linear relationships between the selected features and drug response, 
multivew learning integrated heterogeneous input data (views), even various representations of 
the same data set, into a single model, multitask learning shared information across all drugs 
implying simultaneous modelling, and finally Bayesian inference handled uncertainty from 
small sample size. Overall, BEMKL demonstrated improved predictive performance as depicted 
by the significant increase of signal-to-noise ratio (Costello et al., 2014). A variation of 
BEMKL is component-wise MKL (cwKBMF)* which has the ability to identify groups of 
output variables and apply MKL providing supplementary information regarding the biological 
and structural characteristics of the drugs. In this manner it further refines the use of prior 
knowledge for various subsets, such as pathway information, thus enabling one the link the 
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target to the drug’s mechanism of action (Ali and Aittokallio, 2019, Ammad-ud-din et al., 
2016). The STREAM* algorithm that combines Bayesian inference with Ridge regression is 
another paradigm of integrated approach trained and tested on public data (Neto et al., 2014) 
whereas, improved prediction was reported when Elastic net was combined with Principle 
Component Analysis (Park et al., 2014). Network-based data representations is a 
noteworthy method in which similarity networks among cell lines and between drugs 
are built independently, based on their expression and structural correlations, 
respectively. Subsequently, the two networks are integrated by linking the components 
of the first (cell lines) with the corresponding items (drugs) of the second producing a 
weighted model that reported drug response predictions (Fey et al., 2015; Zhang et al., 
2015; Wang et al., 2014). It is apparent that the list of methodologies will grow as long 
as the “philosopher’s stone” of machine learning has yet to be invented. It is possible 
that the key to this challenge lies in artificial neural networks (Table 2) as discussed in 
section 3.  
     Once the desired computational algorithm is selected, it must be trained to the input 
data (Figure 3). During training, fine tuning of the algorithm parameters will lead to 
the model with optimal performance. The most widely used method in order to optimize 
the model parameters, without over-fitting, is k-fold cross-validation (KF-CV)* (Stone 
M., 1974). According to KF-CV the data item set is divided in k subsets and the k-1 
ones are used for training, while the model is evaluated in the kth item set. The process 
is iterated until all subsets are trained. Subsequently, the trained model is evaluated 
applying various metrics of performance, depending on the type modelling (regression 
vs classification) (Table 4). Recently, the power for drug response prediction was 
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shown to be further boosted by a process termed transfer learning (TL). TL is a way 
of incorporating supporting information among different cell lines. In principal, training 
data include expression profiles and drug responses of tissue-specific cell material (cell-
lines/samples) as well as material of related origin (tissue-type), while only expression 
status is required for the testing samples (Turki et al., 2018).  For confusion avoidance 
it must be noted that the term Transfer Learning is also used in machine learning with 
Artificial Neural Networks where the model weights trained in one subdomain are 
transferred to another. This procedure has been shown to reduce training time and 
increase predictive accuracy (Weiss et al., 2016).  
2d. Testing the prediction models:  The ultimate goal of training is to build a model 
that fits to data beyond the ones utilized for developing the model (Figure 3). The best 
way to test the latter it is to implement it to blind data sets (Figure 3), preferentially 
clinical panels as the final objective of the whole workflow is to deliver tools that could 
help towards identifying tailored therapies for individual cancer patients (precision and 
personalized oncology) (see following sub-section 2e). In case a fully trained model 
fails to generalise then we are dealing with overfitting of the model (Dietterich T., 
1995). Overfitting corresponds to an analysis that is adapted too close or exactly to a 
specific data set (the training data set) and falls short to predict additional data reliably, 
a.k.a fails to generalise. On the other end, there is underfitting when an in silico 
pipeline is unable to capture the underlying structure of a particular data set. In 
machine learning these conditions are termed overtraining and undertraining, 
respectively (Dietterich T., 1995). Especially, overfitting represents a crucial topic in 
the machine learning community and a number of factors appear to be responsible, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
with the amount and diversity (number of features >> samples) of the training data 
being the most important. The discrepancy in model performance in testing vs 
training steps is mathematically reflected by cost functions (Mehta et al., 2019) and 
the aim is to minimize as much as possible the cost effect. This is achieved by a 
process called regularization that intends to reduce the variance by increasing the 
bias in a step-wise manner. In simple words, regularization, which among others can 
be achieved with L1 (Lasso) or L2 (Ridge) penalisation, in combination with KF-CV 
schemes optimizes the parameters of the model and delivers the best model for 
eventual clinical validation.  
2e. Clinical applications and challenges to be met: At the clinical level, research has 
been hampered mostly by the lack of large clinical cohorts that include both detailed 
“omic” data, especially genomic and transcriptomic profiles and responses to 
therapeutic agents. Most of the training-testing scenarios, as mentioned, are based on 
publicly available cell-line data resources (Table 5). Although the worth of cancer cell 
lines in everyday cancer research cannot be questioned, particularly in data mining 
procedures, as they offer a rapidly available set to screen (see section 4), their ability to 
develop drug prediction models for direct clinical use poses certain challenges 
(Caponigro and Sellers, 2011; Ross and Wilson, 2011). The most important one is 
that cancers are heterogeneous in nature and molecular matching with a cell line is not 
feasible, leading to leak of information during the in silico analysis (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011; Turajlic etal., 2019). It has been 
suggested and shown that this hurdle can be circumvented by acquiring fresh patient 
material, keeping it under short-term culture; thus capturing better tumor heterogeneity 
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and the genomic/transcriptomic profile of the primary tumor site (Tentler et al., 2012; 
Day et al, 2015). Another important issue it that cell lines lack the influence of the 
tumor microenvironment (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 
2011). The tumor-microenvironment interplay determines not only cancer development 
but in certain ways also response to treatment (Wu and Dai, 2017).  
     As a result of these constrains there is a pressing need to evaluate the in silico 
technology that is constantly developed in “real patients”. In this vein, there are a 
number of studies that have implemented this approach testing machine learning 
models in patient-derived data from clinical trials or other patient cohorts The most 
prominent ones are subsequently presented and discussed (see also Table 5). Geeleher et 
al. (Geeleher et al., 2014) trained models (Ridge Regression – Table 2) on gene expression data 
and drug responses from the Cancer Genome Project that is a subset of the GDSC, and tested 
them independently on publicly available data (TCGA*) (Table 3) from clinical trials in 
myeloma and non-small-cell lung cancers (NSCLC)*. Another group following a breast cancer 
cell-line based training approach but applying other algorithms (Support Vector Machine and 
Random Forest – Table 2) tested the built model in independent patient-derived data from 
TCGA (Daemen et al., 2013). On both occasions, the cell-line trained models predicted the 
therapeutic response, including relapse-free survival. The Biomarker-integrated Approaches of 
Targeted Therapy for Lung Cancer Elimination (BATTLE)* study represents an important 
patient data source to evaluate (Kim et al., 2011) and discover consequential links between 
molecular markers and drug response. Based on this data resource, Byers and colleagues 
applying hierarchical clustering and principal component analysis (Table 2) identified a 76-
gene expression signature that could distinguish non-small cell lung cancer samples with and 
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without EMT (epithelial to mesenchymal transition)* features, demonstrating resistance of the 
former to EGFR* inhibitors and how to overcome it (Byers et al., 2013). Likewise, using the 
BATTLE trial study Blumenschein et al, developed a gene expression signature of sorafenib 
efficacy (Blumenschein et al., 2013). Implementing an elastic net model (Table 2) in B-cell 
lymphoma cell lines with available gene expression datasets, Falgreen and collaborators 
generated a resistance gene signature in diffuse large B-cell lymphoma patients treated with 
CHO (Cyclophosphamide, Doxorubicin and Vincristine) (Falgreen et al., 2015). In colorectal 
cancer, Guinney et al., showed the prospective clinical utility of modelling specific cancer 
phenotypes and molecular traits. Specifically, training an elastic net model (Table 2) on a large 
series of colorectal cancer tissues according to their K-ras phenotype they were able to predict 
resistance to cetuximab, an anti-EGFR antibody used in K-ras wild-type colorectal cancer 
patients (Guinney et al., 2014). Using an iterative rule-based approach Chen et al., 
(Chen et al., 2015) revealed in ovarian cancer a 61-transcript expression signature for 
predicting patient’s response (poor vs good survival groups) to platinum-taxane 
chemotherapy. Notably, when the expression signature was combined with BRCA1/2* 
mutation status, a traditional prognostic marker for ovarian and breast cancer, patient 
stratification was further improved. The latter signifies the importance of combining 
molecular features, in certain cases.  
     Overall, the encouraging results of these studies render essential: i) the formulation 
of large patient-derived data-bases that will include apart from traditional clinical 
information detailed molecular high-throughput profiles and ii) a “methodological road 
map” that will guide the scientific community (basic researchers, bioinformaticians and 
clinician) in selecting the “best tool” for the “right question”.       
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3. Deep Learning neural networks (DLNN): an emerging “key player” 
    A new promising player with increased performance in the “arena” of machine learning is 
neural networks (Table 2). Particularly, its advanced form, Deep Learning neural networks 
(DLNN)*, have the ability to “understand” complexity and multidimensionality, while have been 
effectively applied in various fields (e.g. image analysis, text mining, etc.) with increased 
classification accuracy compared to classical computational methods (Figure 4a) 
(Schmidhuber, 2015). DLNN is based on the modelling of high-level neural networks in flexible, 
multilayer systems of connected and interacting neurons, which perform numerous data 
abstractions and transformations (LeCun et al., 2015) (Figure 4b).  
    The basic unit in the model (Figure 4c) is the neuron, a biologically inspired model of the 
human neuron. In humans, the varying strengths of the neurons’ output signals travel along the 
synaptic junctions and are then aggregated as input for a connected neuron’s activation. In the 
DLNN models, the weighted combination (α = Σni=1 wixi + b) of input signals is aggregated, and 
then an output signal f(α) transmitted by the connected neuron. The function f represents the 
nonlinear activation function used throughout the network and the bias b represents the neuron’s 
activation threshold. Multi-layer, feed-forward neural networks consist of many layers of 
interconnected neuron units (Figure 4b-c), starting with an input layer to match the feature space, 
followed by multiple (hidden) layers of nonlinearity, and ending with a linear classification layer 
to match the output space. The inputs and outputs of the model’s units follow the basic logic of 
the single neuron described above. Bias units are included in each non-output layer of the 
network. The weights linking neurons and biases with other neurons fully determine the output 
of the entire network. Learning occurs when these weights are adapted to minimize the error on 
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the labelled training data. More specifically, for each training example j, the objective is to 
minimize the loss function, L(W, B | j). After the completion of the Test-set prediction, the 
classification performance is measured by calculating the Area Under the Curve (AUC)* of the 
ROC-curve, Youden’s Index, Sensitivity, Specificity, Accuracy (ACC)*, Positive and Negative 
Predictive Values (PPV and NPV)* and False Positive Rate (FPR)* of the prediction (Table 4).  
In a recent surge of interest, DLNN has been effectively applied to extract features from 
various large and complex data sets, including predicting drug-target interactions (Wang et al., 
2014b), drug toxicity in the liver (Xu et al., 2015), pharmacological properties of drugs (Aliper 
et al., 2016) and automated diagnosis of histopathology slides (Coudray et al., 2018), among 
others. Altogether, studies using the DLNN architecture demonstrate its suitability for the 
analysis of complex biological data, as it can automatically construct complex features and 
allows for multi-task learning (Bengio et al., 2013). One of the main shortcomings of DLNNs 
apart from the computationally intensive long training times required, is their tendency to overfit 
due to the huge number of available model weights through fully connecting multiple hidden 
layers. This problem was however effectively addressed by a regularisation technique called 
dropout (Hinton et al., 2012). Dropout reduces overfitting by omitting a random percentage of 
the feature detectors on each training round, thus allowing the successful generalisation of the 
DLNN.  
    To the best of our knowledge and at the time of preparation of this review, there is only one 
report applying Deep Learning for response to therapy in clinical settings, namely Chiu and 
collaborators (Chiu et al., 2019) who applied deep learning models to predict drug response in 
9059 tumors of 33 cancer types from TCGA. The authors identified as effective, drugs that are 
known to be potent in specific cancers, such as EGFR inhibitors in non-small cell lung cancer, as 
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well as novel drugs for a specific type of cancer, such as vinorelbine for TTN-mutated tumors. 
Notably, the authors of the aforementioned study used a type of DLNN called autoencoder. 
Autoencoders are unsupervised DLNNs that are trained to reconstruct their input (Table 2) 
(Hinton et al., 1994). In order for the networks to do so, they learn the most meaningful 
structures and relationships among the input features by compressing the information through a 
bottleneck hidden layer in the middle of the hidden layer stack that forces the network to discard 
all unnecessary information. These kind of networks have a wide range of applications, namely: 
(i) Dimensionality reduction, where the neurons of the bottleneck layers are used as non-linear 
multi-dimensional principal components (Taghanaki et al., 2017), 
(ii) Compression, where the structure learned is stored as the compressed version of the original 
information (Tan and Eswaran, 2011), 
(iii) Missing value imputation, where the intricate relationships of the input features that were 
learned were used to impute missing values (Talwar et al., 2018), 
(iv) Denoising, where the structure learned was used to reconstruct the input without the noise 
which was discarded during the learning process (Creswell and Bharath, 2019). 
    Interestingly, Rampášek and collaborators demonstrated the use of deep autoencoders to 
integrate drug response information along with gene expression perturbation for building more 
effective predictive models of drug response in cell lines (Rampášek et al., 2019). 
 
4. A novel in silico screening process based on Association Rule Mining (ARM study)  
    Given their molecular profiling data, both large cell-line panels (CCLE and GDSC) have been 
utilized in attempts to identify biomarkers for predicting drug response of specific cancer cell-
lines (Barretina et al., 2012; Garnett et al., 2012). Previous efforts to define biomarkers of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
drug response primarily employ general linear models, penalized linear modelling techniques, 
to identify cooperative interactions among multiple genes and transcripts across the genome and 
define response signatures for each drug (Forbes et al., 2015). While efficient, these algorithms 
suffer certain limitations since when used for feature selection, as described in previous studies 
(Barretina et al., 2012; Garnett et al., 2012), the derived results are simple associations 
between a single gene and drug response. If, however, one wishes to explore the relevance of a 
more complex feature-space relationship (two or three-way interactions among simple features in 
all possible combinations) to the drug response, the process is convoluted. This is primarily due 
to the fact that these algorithms fall-short in automatically evaluating all possible combinations 
including multi-way interactions of a large number of features against a response variable 
without further implementation. Furthermore, multi-feature models generated by such algorithms 
are difficult to interpret in terms of biological relevance. When utilised as a classifier to predict 
whether a sample will be resistant or sensitive to a drug, given its molecular profile, the general 
linear algorithms do not perform optimally. This is due to the fact that at the core of these 
algorithms lays linear regression, as opposed to non-linear classifiers, such as Random-Forests 
and Kernel-based models. The later have been shown to outperform the general linear 
algorithms in the task of actually predicting drug response, as demonstrated in a recent proof of 
concept study on a panel of 53 breast cancer cell lines evaluated for pharmacological response 
against 28 anti-cancer drugs (Iorio et al., 2016).  
    A promising methodology used by large businesses that overcomes the primary limitations of 
the general linear models for feature selection, yet capable of analysing enormous volume of 
transaction data to discover all possible associations between the data features is the Association 
Rule Mining (ARM) (Table 2, Figure 5). Previous studies moved along the same lines to 
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produce easily interpretable logical rules out of similar pharmacogenomic datasets (Iorio et al., 
2016; Masica and Karchin, 2013). Within this context we developed a resource of rules linking 
candidate genes as cancer drivers to drug response using this in silico methodology. The reason 
is that association rule mining provides an efficient big-data ready framework that is able to 
evaluate a huge sample space of associations among features including multi-way interactions 
with more than 30 different objective measures (Tan et al., 2004). Additionally, the output of the 
algorithm comes in the form of easily interpretable rules, making knowledge extraction and 
meta-analysis a more straightforward process.  
    First, a comprehensive dataset was constructed using the GDSC and Cosmic Cell line project 
(CCLP) databases (Figure 5a). This task was achieved by merging data from the CCLP and 
GDSC. GDSC was used (Garnett et al., 2012) as a drug response data source for 251 
therapeutic compounds, which provided IC50 values for each compound, as well as information 
on tissue origin. Information on total gene mRNA expression, number of DNA copies and 
mutational status was obtained from the Cosmic Cell line project (CCLP) (Forbes et al., 2015). 
CCLP was preferred over CCLE as a data source since it provides profiles on 1,074 cancer cell 
lines and is not limited to the mutational status of only 1,600 genes, as is the case with CCLE. 
GDSC contains dose response data for the 1,001 CCLP cell lines only and therefore only those 
were used in our analysis. Although NCI-60 contains the largest number of therapeutic 
compounds tested for pharmacologic activity, it was excluded as a data source, as the number of 
cell lines presented is very small compared to the other resources used. A summary of the 
compiled pharmacogenomics dataset is presented in Supplementary Figure 1. 
    Applying the Apriori algorithm (Agrawal et al., 1993) significant associations from all of the 
possible combinations of the features from the main dataset (tissue of origin, gene expression, 
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mutation status, CNV plus drug response) were extracted, in order to generate a large rule-set, 
containing all tissue-to-gene, tissue-to-drug, gene-to-gene, gene-to-drug and drug-to-drug 
associations. The main bottleneck in the application of association rule mining is the 
computationally intensive requirements. While this will likely improve as computing power 
increases, due to hardware limitations in the currently presented resource we maintained only the 
tissue-to-drug, gene-to-drug and drug-to-drug associations for the present study. Gene-to-gene 
associations, which constitute an enormous RAM intensive rule-set, were discarded. Details and 
metrics of the Apriori algorithm can be found in Figures 5 and 6. The basic interest metrics, 
available by the arules R package, and utilised were support, confidence and lift. Support is the 
frequency of the rule occurrence in the total dataset, while confidence is the frequency of rule 
occurrence in the cases of the dataset fulfilling the left hand side of the rule and lift is the factor 
by which, the co-occurrence of A and B exceeds the expected probability of A and B co-
occurring, had they been independent. Relationships between confidence and support metrics 
(for top 10,000 one-way and 100,000 two-way rules) are visualized in the scatterplots in 
Supplementary Figure 2. To select significant non-random rules by controlling the false 
positive rate (FPR)*, a randomization approach was applied based on running the Apriori 
algorithm on a permuted version of the initially employed dataset (see “Association Rule 
Mining: Apriori Algorithm / Dynamic Thresholding” in Supportive material section). At 
5% FPR, 1,326,251 1-way rules were identified: 2,124 of them where tissue to drug, 989,163 
gene-expression to drug, 110,442 gene-CNV* to drug and 224,522 gene-mutation to drug 
(Supplementary File 1, “one_way_rule_count”). All identified rules are available online via an 
interactive Rshiny application: https://compbio.nyumc.org/drugs/ (Supplementary File 2). 
Representative outputs from the web application, confirming prior-knowledge, are presented in 
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Figure 7 and Supplementary Figure 3. The user can search for a tissue, gene or drug of interest, 
filter using different metrics and visualize the results and download the data. The biological 
relevance of the rules generated was examined both computationally (based on prior knowledge) 
and experimentally, as demonstrated in the following sections. 
 
4a. Rule verification based on prior knowledge 
    To explore the potential biological relevance of our statistically significant association rules, 
we examined whether: (1) known predictors of drug response are present in our rule set, and, (2) 
drugs and their targets are present together in sensitivity-associated rules if the target(s) are 
mutated and/or over-expressed. 
 
MAPK and PI3K signalling pathway 
    Initially, we followed an unbiased approach, where we performed k-means clustering (see 
“Association Rule Mining – Apriori Algorithm” in Supportive material section) of the 1000 
rules with the largest support (k=50) for drug sensitivity associated with: (a) the ERK/MAPK* 
signalling, and, (b) the PI3K* signalling (Supplementary File 1: “1-way rules” and 
Supplementary File 3: “Drugs”). First, the clustering of the top rules associated with 
ERK/MAPK signalling revealed that mutated BRAF* (known to be essential to ERK/MAPK 
signalling (McCain, 2013)) was present among the top 50 cluster centres (Figure 8a). 
Additionally, this clustering revealed that the melanoma cell lines are expected to be highly 
sensitive to BRAF and MEK* inhibitors, a prediction that can be verified in the literature with 
studies showing that combined BRAF and MEK inhibition is one of the most effective 
treatments for melanomas (Figure 8a) (Long et al., 2014). The half maximal inhibitory 
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concentration (IC50) values of the drugs included in this group indicate increased sensitivity for 
melanoma cell lines and for cell lines carrying mutated BRAF as compared to the total dataset 
(p-value < 0.05) (Figure 8b). Second, the clustering of the top rules associated with PI3K 
signalling revealed the presence of mutated PTEN among the top 50 cluster centres (Figure 9a). 
PTEN* is a direct PIK3CA* suppressor (Carracedo and Pandolfi, 2008) that is frequently 
mutated in cancer with loss-of-function mutations (Rodriguez-Escudero et al., 2011), which in 
turn leads to increased PIK3CA activity. Notably, mutated PIK3CA was also present in the 
mutated-PTEN cluster (Figure 9b, right panel). Given that both, PTEN and PIK3CA, belong to 
the same pathway, the fact that the onco-suppressor (PTEN) is deactivated at the same time that 
the oncogene (PIK3CA) is further activated by hot-spot gain-of-function mutations can be 
conceptualized as a variation of the Knudson double-hit hypothesis (Knudson, 1971). IC50 
heatmaps (Figure 9c, right panel) indicate that cell lines with PIK3CA mutations are 
significantly more responsive (p-value < 0.01) to inhibitors targeting the PI3K pathway 
compared to cell lines with wild-type PIK3CA, which seem to be resistant to the same inhibitors. 
These observations confirm that clustering of significant rules can provide relevant insights 
regarding the molecules that are related to responsiveness to certain classes of drugs.  
 
Multiple drug response, p53 and PARPi resistance 
    To further validate our models, we also looked for specific genes known to be implicated in 
drug resistance and/or sensitivity. We observed that the ABCB1 gene that encodes the Multidrug-
Resistance-1 (MDR1)* protein, was found in our rule set to be linked with resistance to multiple 
drugs when it is over-expressed (55 out of 57 drugs), while when suppressed it is linked with 
sensitivity (7 out of 9 drugs) (Supplementary File 1: “1-way rules”). In addition, our rules 
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indicate that EGFR over-expression and suppression are significantly associated with Lapatinib 
sensitivity and resistance, respectively, which is in agreement with previous findings 
demonstrating that EGFR expression can efficiently affect response to this tyrosine kinase 
inhibitor (TKI)* (Rusnak et al., 2007) (Supplementary  File 1: “1-way rules”). Moreover, we 
observed that known predictors of drug response are highly ranked in our rule set. For example, 
suppressed NAD(P)H dehydrogenase 1 (NQO1)* and over-expressed MDM2, a p53 inhibitor, 
which are known predictors of sensitivity for the drugs 17-AAG (Tanespimycin) and Nutlin-3, 
respectively (Kelland et al., 1999; Muller et al., 2007), are present in our rule-set with lift 
values 4 and 4.06, respectively, which are in the top 25% quantile of lift values in our list of 
significant 1-way rules (Supplementary File 1: “1-way rules”). Of note, three recent reports 
demonstrating that inactivation of genes encoding subunits of the shieldin complex (REV7, 
SHLD1-3)* cause resistance to poly(ADP-ribose) polymerase inhibition (PARPi)* in BRCA1-
deficient cells and tumours (Mirman et al., 2018; Noordermeer et al, 2018; Dev et al., 2018), 
were also confirmed by the Apriori data mining process (Supplementary File 1: “1-way rules”; 
Figure 7 and Supplementary Figure 3). In addition, and within the same context, we identified 
in the literature a list of 96 genes whose status was experimentally linked with PARPi (Figure 10; 
Supplementary File 1). We queried our database to identify rules associating these 96 genes 
with all PARP inhibitors enlisted. We found a total of 166 rules describing associations of 71/96 
(74%) genes with PARP inhibitors. Specifically, we spotted 24 rules with gene mutations, 13 
rules with gene copy-number variations (CNVs) and 129 rules with gene-expression 
(Supplementary File 1, “PARPi”). To exclude the possibility that the observed matches were 
due to chance alone, we performed a Monte-Carlo simulation taking into account all relevant 
parameters (see Supplementary Materials, section 2.5). We demonstrated (Figure 10) that the 
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number of the reported matches could not have been observed randomly (p-value = 
0.008766261), highlighting the effectiveness of the data mining process applied.   
 
Drug response in small-cell lung cancer  
    The following two examples indicate how the association rules, when allowing for interactions 
(2-way), can be used to gain further insight in the molecular mechanisms of drug resistance in 
Small-Cell Lung Cancer (SCLC)* and identify potential points of intervention. 
    The 1-way rules indicate a large pattern of multi-drug resistance (93 drugs) involving SCLC 
(Supplementary File 1: “1-way rules”). SCLC accounts for approximately 15% of all lung 
cancer cases (Planchard and Le Pechoux, 2011). It is considered one of the most aggressive 
malignancies mainly due to the rapid development of multi-drug resistance (Yeh et al., 2005), 
which is in agreement with our finding. The 2-way rules (Supplementary File 1: “2-way 
rules”), indicate that the Growth hormone-releasing hormone (GHRH)* over-expression greatly 
increases the lift-value (hence statistical significance) to 39 of the above drugs, suggesting it may 
be involved in multi-drug resistance mechanisms. It is known that inhibition of GHRH activity 
using antagonists yields high anti-tumour activity by impending cell proliferation (Kiaris et al., 
2000; Popovics et al., 2017). Furthermore, GHRH activity has been linked to drug-resistance in 
triple negative breast cancer (Perez et al., 2014). Herein, by including interactions in association 
rule mining we were able to infer that GHRH antagonists could be potentially used in 
combination with specific chemotherapeutic agents for the effective treatment of SCLC. This is 
further supported by the fact that in preclinical models monotherapy with novel GHRH 
antagonists resulted in significant suppression of SCLC and NSCLC tumor growth (Wang et al., 
2018). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
    In a separate example, with the 1-way rules (Supplementary File 1: “1-way rules”), we 
observed statistically significant resistance to Obatoclax-Mesylate, a BCL*-family inhibitor, with 
a lift-value of 2.47 in 22 out of 66 SCLC cell lines (33.3%). With the 2-way rules 
(Supplementary File 1: “2-way rules”), we noted that SMAD3* down-regulation greatly 
increases the lift-value to 4.77, since resistance to Obatoclax-Mesylate is observed in 9 out of 14 
SCLC cell lines under-expressing SMAD3 (64.3%). SMAD3 is known to promote apoptosis 
through transcriptional inhibition of BCL-2 (Yang et al., 2006). SCLC cell lines under-
expressing SMAD3 clearly possess increased levels of BCL-2, which correlates well with the 
phenotype of resistance to a BCL-2 inhibitor, such as Obatoclax-Mesylate. In this example, 
association rule mining precisely elucidated a specific mechanism of resistance of SCLC tumors 
to BCL-family inhibitors, by highlighting a unique molecule that presents high mechanistic 
relevance to BCL-inhibition.   
 
4b. Rule Experimental Validation 
Drug-specific target selection and experimental validation 
    The generated 1-way rule-set consists of 1,326,251 statistically significant rules 
(Supplementary File 1: “1-way rules”) as selected by the Dynamic Thresholding procedure. In 
order to ascertain that our rule-set consists of meaningful rules in an unbiased and systematic 
way, we devised a systematic 4-step rule-based gene-selection algorithm (Supplementary 
Figure 4b1; “Validation procedure” in Supportive material section) to identify novel 
therapeutic targets and then we proceeded with their experimental validation. Particularly this 
algorithm associates gene expression with drug resistance patterns across a big number of 
diverse drugs and is designed to narrow down the long list of more than 16,000 genes to one with 
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only few selected candidates, the silencing of which should increase the efficacy of a specifically 
applied treatment. Using this algorithm 128 rules corresponding to 128 genes per drug were 
identified on average, summing to a total of 30,639 rules (Supplementary File 3: 
“si_t_resistance_genes_all_drugs”). We applied the algorithm on all available drugs 
(Supplementary File 3: “t_resistance_genes_all_drugs”), but in order to provide a practical 
application we focused on the efficacy enhancement of Doxorubicin (Supplementary File 3: 
“DoxoTargetsSelectionResGenes”). The experimental validation of the algorithm was designed 
to monitor whether Doxorubicin treatment in combination with the silencing of each identified 
target resulted in a synergistic increase in efficacy across four cancer cell lines, namely A549 
(lung carcinoma), NCI-H1299 (lung carcinoma derived from metastatic site), MCF7 (breast 
adenocarcinoma derived from metastatic site) and Saos-2 (osteosarcoma). Our algorithm selected 
72 out of 16445 total genes available from our initial dataset (Supplementary File 3: 
“DoxoTargetsSelectionResGenes”). We randomly chose five targets from the list, for 
experimental validation, namely MAGI3*, POF1B*, PDIA3*, CD151* and NPTN*, none of which 
are specifically connected with Doxorubicin efficacy in the biomedical literature 
(Supplementary File 3: “DoxoTargetsSelectionResGenes”). As predicted by our algorithm, in 
all cases siRNA treatment led to a significant sensitization of the examined cells to Doxorubicin 
(Supplementary Figure 4a, 4b1, 4b2i-ii, 4c1, 4d2; Supplementary File 3: 
“Doxorubicin_IC50”; Supplementary Materials). Decreased soft agar colony formation 
further supported these findings (Supplementary Figure 4e1). Potential mechanistic insights 
underlying these results are proposed in Table 6. As a negative control, we reversed the 
algorithm for all drugs to select genes that upon silencing should decrease efficacy of 
Doxorubicin (Supplementary File 3: “si_t_sensitivityGenes_all_durgs”). We randomly chose 
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again 5 targets from the list for experimental validation namely TP53*, CTCF*, CCND3*, 
ARHBD1B* and ZCCHC7* (Supplementary File 3: “DoxoTargetsSelectionSensGenes”). In 
accordance to our predictions, siRNA treatments led to a significant increase in resistance to 
Doxorubicin (Supplementary Figure 4a, 4b1, 4b3i-ii, 4c2, 4d3, 4e2; Supplementary File 3: 
“Doxorubicin_IC50”; Supplementary Materials). Presumable underlying mechanisms of 
increased resistance are proposed in Table 7.  
 
ID1 as a biomarker of response to PI3K-targeted therapies 
    After demonstrating that rule-clustering delivers relevant results, we present an example of 
how the rules can be used to gain novel insights on biomarker discovery for drug response. The 
PI3K signalling pathway rule clustering, links the suppression of the ID1* gene to sensitivity to 
10 out of 16 drugs targeting the PI3K pathway with high lift and support values (Figure 9a). 
Inhibitor of DNA binding 1 (ID1) is a transcription regulator, widely reported as linked to 
tumour metastasis when over-expressed (Eisfeld et al., 2017; Jin et al., 2016) and known to 
activate the PI3K pathway (Li et al., 2012), while inhibition of ID1 expression suppresses cancer 
invasion and progression (Murase et al., 2016; Tominaga et al., 2016). IC50 heatmaps (Figure 
9b,c; left panel) indicate that cell lines under-expressing ID1 are significantly more responsive 
to inhibitors targeting the PI3K pathway compared to cell lines over-expressing ID1 (p < 0.01). 
These results imply that apart from being used as a therapeutic target per se, ID1 could be 
utilised as a predictive biomarker for response to PI3K-targeted therapies, as its expression 
seems to distinguish sensitive from resistant cell lines more efficiently than the actual PIK3CA 
mutation status (Figure 9b,c; right panel; Figure 11a). Within this context, we recently 
demonstrated that chronic expression of the tumor-suppressor p21WAF/Cip1, in a p53-deficient 
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environment, exhibited an oncogenic behaviour, by “escaping” from the antitumor barrier of 
senescence and generating aggressive and chemo-resistant clones (Figure 11b) (Galanos et al., 
2016). In line with the above observations, ID1 was found up-regulated in these cells (Galanos 
et al., 2016). To experimentally validate the in silico prediction, we interrogated the sensitivity of 
the p21WAF/Cip1 “escaped” clones for two PI3K inhibitors, namely CAL-101 and ZSTK474 from 
our panel (Figure 9a; Figure 11a), before and after ID1 silencing. As shown in Figure 11c (left 
panel), the “escaped” p21WAF/Cip1 cells showed IC50 values of 0.141 μM and 1.26 μM for CAL-
101 and ZSTK474, respectively. Concurrent silencing of ID1 with administration of each 
inhibitor significantly reduced the corresponding IC50 values and decreased colony formation 
(Figure 11c right panel), suggesting that inhibition of ID1 confers to PI3K chemo- sensitivity in 
accordance with the in silico model (Figure 9; Figure 11a).  
    Moreover, in the ID1 rule-cluster, over-expression of 4 other genes was found to be highly 
related with sensitivity to PI3K-pathway inhibitors, namely ZNF22*, GMIP*, LYL1* and 
SAMSN1* (Figure 9b, left panel). Interestingly, LYL1 (Lymphoblastic Leukemia Associated 
Hematopoiesis Regulator 1) is known to be implicated in the development of leukemia (Meng et 
al., 2005) and lymphoma (Zhong et al., 2007), both representing promising target groups for 
anti-PI3K/mTOR* agents (Bertacchini et al., 2015; Blachly and Baiocchi, 2014). SAMSN1 
(SAM Domain, SH3 Domain And Nuclear Localization Signals 1) is an intriguing case since it 
appears to act as a tumour suppressor in certain malignancies such as multiple myeloma (Noll et 
al., 2014), gastric cancer (Kanda et al., 2016), lung cancer (Yamada et al., 2008) and 
hepatocellular carcinoma (Sueoka et al., 2015), whereas its over-expression has been associated 
with poor survival in glioblastoma multiforme (Yan et al., 2013), a malignancy where drug 
resistance represents a major challenge (Haar et al., 2012). Its detection in the rule-set concurs 
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with recent developments suggesting that targeting the PI3K pathway could be a potential 
therapeutic option to overcome drug resistance in glioblastoma multiforme (Sami and Karsy, 
2013).   
 
CDC6 overexpression as an indicator of resistance to MAPK pathway inhibitors  
    Among the results extracted from the Apriori data mining process we noticed three rules that 
drew our attention as they were related with the role of deregulated replication licensing in 
cancer, one of the main research fields of our group (Karakaidos et al, 2004; Bartkova et al., 
2006; Liontos et al., 2007; Sideridou et al., 2011; Petrakis et al., 2016; Galanos et al., 2016). 
They linked CDC6 (Cell division cycle 6)* overexpression (termed oncogenic CDC6) with 
resistance to MAPK (Mitogen-Activated Protein Kinase) inhibition (Figure 12a). In most cases, 
this type of resistance is associated with mutations that either render the MAPK pathway 
insensitive to treatment or reactivate alternative components of the signaling route bypassing the 
inhibitory block (Logue and Morrison, 2012; Pritchard and Hayward, 2013; Varmus et al., 
2016) (Figure 12b). We and others have shown that CDC6 is deregulated in many types of 
cancer from their earliest stages and is an indicator of poor prognosis (Karakaidos et al, 2004; 
Bartkova et al., 2006; Liontos et al., 2007; Sideridou et al., 2011; Petrakis et al., 2016; 
Galanos et al., 2016) (Supplementary Figure 5a). According to the oncogene-induced DNA 
damage model for cancer development (Halazonetis et al., 2008), oncogenic CDC6 fuels 
genomic instability by causing replication stress and DNA damage (Liontos et al., 2007; 
Gorgoulis et al., 2018; Petrakis et al., 2016; Sideridou et al., 2011; Galanos et al., 2016; 
Galanos et al., 2018; Komseli et al., 2018). As DNA damage accumulates the DDR (DNA 
Damage Response)* and the error-free repair pathways are overwhelmed leading, due to selective 
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pressure, to inactivation or exhaustion of vital DDR/R (DDR and Repair) components. 
Consequently, there is a shift to error-prone repair that leads to escape from the anti-tumor 
barriers of senescence and apoptosis, by generating a landscape of mutations that promote cancer 
development (Halazonetis et al., 2008; Galanos et al., 2016; Galanos et al., 2018; Gorgoulis 
et al., 2018). As CDC6 functions downstream of the RAS-RAF-MEK1/2-ERK1/2 pathway 
(Lunn et al., 2010; Liu et al., 2010; Steckel et al., 2012; Di Micco et al., 2006; Sideridou et 
al., 2011; Hills & Diffley 2014; Petrakis et al., 2016) and mutational activation of the MAPK 
signalling is a prominent feature of many cancer types (Fang and Richardson, 2005; Dhillon et 
al., 2007; Kim and Choi, 2010; Logue and Morrison, 2012; Pritchard and Hayward, 2013), 
we postulated that the aforementioned rules (Figure 12a) possibly reflect one way of how 
oncogenic CDC6 promotes cancer development. In particular, tumors with high levels of CDC6 
would at some point select to rewire cellular signalling to another pathway, parallel to MAPK 
cascade that does not comprise RAF and MEK1/2*, thus rending these tumors unresponsive to 
MEK1/2 inhibitors, such as Trametinib or RDEA119. In other words, it is most unlikely that a 
RAF or MEK1/2 inhibitor would be effective when a downstream effector of this pathway is 
overexpressed and active. From cancer biology perspective activation of a parallel pathway 
would exert an additive tumor promoting effect phenocopying the activation of the RAS-RAF-
MEK1/2-ERK1/2 pathway, as suggested in colon cancer (Hanahan and Weinberg, 2010). 
    To test this hypothesis we employed a CDC6-inducible normal cellular model that 
recapitulates in relatively short period all stages of cancer development (Komseli et al., 2018) 
(Figure 12c). Briefly, and in accordance to our model (Halazonetis et al., 2008), chronic CDC6 
expression triggered the anti-tumor barrier of senescence (precancerous stage) that was 
eventually overridden leading to the emergence of aggressive clones (cancerous stage) (Figure 
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12c) (Komseli et al., 2018). We performed three biological replicates of this cancer evolution 
experiment and examined by WGS (whole genome sequencing) means the genetic alterations 
acquired. Interestingly, and in accordance to our assumption, among the alterations found, all 
three clones harbored an R55T amino-acid substitution located in codon 55 of MAP2K3 
(Mitogen-Activated Protein Kinase Kinase 3) (Figure 12d). This is a key component of the 
stress/cytokines-induced p38 MAPK pathway located upstream of its end-effector, the p38 
kinase (Cuadrado and Nebreda, 2010). It acts in parallel with the RAS-RAF-MEK1/2-ERK1/2 
signaling route and has a significant role in cell proliferation and malignant transformation 
(Cuadrado and Nebreda, 2010; Baldari et al., 2015) (Figure 12b). This mutation has been 
also reported in colorectal cancer 
(https://hive.biochemistry.gwu.edu/biomuta/proteinview/P46734) and potentially affects the 
structure and function of MAP2K3 (see details in Supplementary Figure 5b). Of note, as we 
previously showed the activated p38 pathway promotes colon cancer progression (Gupta et al., 
2014). A strong indication that this mutation is associated with activation of the MAPK p38 
pathway is the increased phosphorylation levels of its downstream effector p38 in the escaped-
from-senescence aggressive clones (Figure 12e). Within the same line and in support to the rules, 
the escaped-from-senescence cells harboring high levels of CDC6 were significantly more 
resistant to the MEK1/2 inhibitor PD98059 than the non-induced (OFF) cells with very low 
CDC6 levels (Figure 12f; Supplementary Figure 5c). 
 
5. Comparison of ARM study with other frameworks 
    We compared our rules with the respective ones identified in various databases, namely GDSC 
(Genomics of Drug Sensitivity in Cancer) (Iorio et al., 2016), CCLE (Cancer Cell Line 
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Encyclopedia) (Barretina et al., 2012) and CTRP (Cancer Therapeutic Response Portal) 
(Seashore-Ludlow et al., 2015) (see Supplementary Materials, Supplementary File 1).  
GDSC-Genomics of Drug Sensitivity in Cancer 
    ANOVA: i) Mutations: Iorio et al., (Iorio et al., 2016) identified 268 one-way mutated gene-
to-drug relationships, of which 82 were matched with our one-way rules (overlap 34.75%). 
Interestingly, for genes bearing clinical relevance such as BRAF, EGFR, P EN, TP53, FLT3*, 
KRAS and PIK3CA, the overlap of our one-way rules with Iorio et al., was: 92.31%, 60.00%, 
100.00%, 30.77%, 33.33%, 83.33% and 100.00%, respectively (Supplementary File 1 "Mut 
Clinically Relevant Iorio V", Figure 13) (Sethi et al., 2013). ii) Copy number variations: They 
(Iorio et al., 2016) identified 10,201 gain/losses related to drug responses, of which 827 were 
also present in our rules (overlap 8.11%). iii) Gene expression: 5361 drug response interaction 
were identified, 1089 of which were also identified by our pipeline (overlap 20.3%).  
    LOBICO: Regarding the comparison of our rules with the multiple relationship models 
generated by Iorio et al., through LOBICO (Iorio et al., 2016), we identified 114 out of a total 
of 1112 LOBICO models that could be compared with our one-way rules, of which 38 were 
present in our rule-set (overlap 33.33%), and 2 rules that could be compared with our two-way 
rules, namely “CDKN2A-loss AND MYC-gain => EpothiloneB-Sensitivity” and “CDKN2A-
loss AND MLL2-mutation=>SB52334-Sensitivity”. Although loss of CDKN2A is connected 
with EpothiloneB and SB52334 Sensitivity in our two-way rule-set (Supplementary File 1 
“two-way rules”), MYC-gain and MLL2-mutation were not identified. It must be noted that the 
1112 LOBICO models contain multiple genes combined together through the logic operators 
AND, OR and NOT which are then connected to a specific drug response. As a result, this 
scheme produces rules that cannot be directly compared to our rule-set. Therefore, no statistical 
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conclusion may be drawn due to the low number of compatible rules extracted. 
CCLE-Cancer Cell Line Encyclopedia 
     Data were drawn from CCLE as follows (Stransky et al., 2015). i) Mutations: 421 mutation-
drug response interactions were identified in the CCLE data-set, with 14 being in common with 
our rules (overlap 3.3%). ii) Copy number variations: From the 103 identified copy number 
variation-drug response interactions, 4 were also found in our rules (overlap 3.9%). iii) Gene 
expression: Finally 7382 gene-expression to drug response interaction where identified, 1000 of 
which were in common with the current study (overlap 13.55%) (Supplementary File 1). 
CTRP-Cancer Therapeutic Response Portal* 
    Seashore-Ludlow et al., was utilized as the CTRP data-source (Seashore-Ludlow et al., 2015). 
The particular analysis was performed at a level connecting gene mutations to drug-cluster wide 
response, the common element of the cluster being the molecular target. An in-house R-script 
(see Supplementary Materials section 2.4) was utilised to subset the CTRP dataset to our 
collection of drugs and identify relevant rules from our dataset. From the 10829 gene mutation to 
drug cluster response interactions, 1811 were represented in our rules (overlap 16.72%).   
 
6. Perspectives and future challenges 
    Hitherto, the degrees of overlap that the various in silico settings demonstrate (Figure 13), 
suggest the necessity of applying multiple analytical techniques to maximize information 
retrieval. Moreover, although all in silico pipelines suffer to certain extent from false positive and 
negative outcomes it is possible that several, at first glance, contradictory results could simply 
reflect a U-shaped curve drug response or behaviour (Figure 14). In other words, deviation from 
optimal activity, either too little or too much has the same impact. A characteristic example is 
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mTOR1, where both, low and high activity, lead to insulin resistance (Laplante and Sabatini, 
2012). The complexity of biological processes is indeed evident in everyday clinical practice. 
For example, not all patients with EGFR mutations respond to treatment with EGFR TKIs 
(Tyrosine Kinase Inhibitors) (Zhong et al., 2017). On the other hand, a subset of patients with 
wild type EGFR also responds to EGFR TKIs (Ulivi et al., 2015; Xu et al., 2016; Koinis et al., 
2018). Likewise, vemurafenib-resistant melanomas that depend on the drug to proliferate can 
become re-sensitized following a "drug holiday period” (Das-Thakur et al., 2013, Schreuer et 
al., 2017). 
     Among the other methods described the screening pipeline based on ARM’s could be 
effectively applied in the future in Biomarker-Guided Adaptive Clinical Trial Designs (Antoniou 
et al., 2016). Patient’s molecular profile can be obtained and compared against the extracted 
from ARM’s gene-drug response rules. These results can form the basis to design appropriate 
sophisticated target gene interventions. Initially they could be tested on patient-derived primary 
2D and 3D cancer cell cultures (Das et al., 2015) and/or on xenograft models (Siolas and 
Hannon, 2013). The most effective schemes could be applied in clinical trials, constant 
monitoring for administration of personalised dosing and use of circulating tumour cell assays 
and ctDNA for early detection of the emergence of resistance (Palmirotta et al., 2018). 
Moreover, the pharmacogenetic databases could be further expanded by increasing the number of 
cancer cell lines, including patient-derived cell lines, as well as by increasing the number of 
therapeutic genes analysed by the system. Additionally, integration of other layers of “omics” 
information, including meta-genomics, proteomics, phospho-proteomics, interactomics and 
metabolomics will further enhance the applicability of this method, eventually increasing the 
power of the presented in silico process. Last but not least, the algorithm may be implemented in 
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a wider expert decision support system (artificially intelligence based) to assist oncologists in 
predicting drug response and selecting the best drug candidates for precision based therapy.  
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FIGURE LEGENDS 
 
Figure 1. The landscape of computer sciences: its “russian-doll”-like organization and its 
relationship with big data. For terminology explanation and further reading see Table 1 and 
accompanying references. 
 
Figure 2. Machine learning algorithms comprise an extensive “universe” of application 
models (reproduced with permission from Dr Jason Brownlee: 
https://machinelearningmastery.com/faq/single-faq/how-do-i-reference-or-cite-a-book-or-blog-
post). For a highlight on the most prominent machine learning applications and their pros and 
cons, see Table 2.  
 
Figure 3. Key steps for building in silico models for drug response. These models comprise 
three steps: i) opting the input data set, ii) selecting the appropriate algorithm (see Table 2 and 
Figure 2 for a highlight on machine learning algorithms) and training it to build a prediction 
model, and iii) testing of the algorithm in unseen data sets. Resources of big input data can be 
from cell lines, animal model or clinical cohorts and type of information include o variety of 
“omics” or clinical data such as gene copy numbers, gene expression, gene mutations, epigenetic 
changes, protein expression, pharmacological responses, survival and others. 
 
Figure 4. Neural Network Architecture. (a) Comparison of prediction performance of Deep 
Neural Networks, an advanced form of neural networks, against other learning algorithms in 
relation to continuously increasing amount of “big-data” [reproduced with permission from Dr 
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Andrew Y. Ng (https://medium.com/syncedreview/andrew-ng-offers-ai-for-everyone-
eac04877773d; https://medium.com/syncedreview/andrew-ng-warns-of-centralized-ai-power-
47a44a 462c8)]. (b) The organization of neurons in multi-layered networks. (c) The single 
neuron as a unit. 
 
Figure 5. Schematic representation of the study design and bioinformatics pipeline. (a) 
Dataset: the full data set was constructed using the GDSC and CCLP databases (see also 
Supplemental Figure 1). (b) Model construction: Association Rule Mining (ARM) was used to 
generate testable hypotheses of genes associated with sensitivity or resistance to specific drugs 
(left panel). (c) Validation: our models were validated computationally and in a variety of in vitro 
experimental settings.  
 
Figure 6. Association Rule Mining (ARM) basic interest metrics. There are three basic 
metrics to describe the power and significance of the rules generated by ARM. Rules are in the 
form of A => B. The feature A is considered to be the Left Hand Side (LHS) of the rule while the 
feature B the Right Hand Side (RHS). Support is the frequency of the rule occurrence in the total 
dataset.Confidence is the frequency of rule occurrence in the cases of the dataset fulfilling the 
left hand side of the rule. Lift is the factor by which, the co-occurrence of A and B exceeds the 
expected probability of A and B co-occurring, had they been independent. Details are presented 
in Supplemental Materials section. 
 
Figure 7. Representative output from the interactive Rshiny web application: 
https://compbio.nyumc.org/drugs/, confirming prior-knowledge on the Shieldin-PARPi 
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association. 
 
Figure 8. Unbiased k-means cluster of top significant rules associated with the ERK-
MARPK signalling pathway. (a) Group-wise Association Rules visualization by k-means 
clustering k=50 of the 1000 1-way rules with the largest support, for the sensitivity state of drugs 
targeting the ERK-MAPK signalling pathway. (b) IC50 heatmaps of drugs targeting the ERK-
MAPK signalling pathway for melanoma versus non-melanoma cell lines and for cell lines 
carrying mutated versus wild-type BRAF.  
 
Figure 9. Unbiased k-means cluster of top significant rules associated with the PI3K 
signalling pathway. (a) Group-wise Association Rules visualization by k-means clustering k=50 
of the 1000 1-way rules with the largest support, for the sensitivity state of drugs targeting the 
PI3K signalling pathway. (b) Zoom-ins of the ID1 and PTEN clusters presented in section-a. (c) 
IC50 heatmaps of drugs targeting the PI3K signalling pathway for cell lines over versus under-
expressing ID1 and for cell lines carrying wild-type versus mutated PIK3CA.  
 
Figure 10. Association Rules related to genes associated with PARP inhibitors response. 
Application of the current pipeline on information recall from 96 literature-derived and 
experimentally verified genes associated with response to PARP inhibitors; Monte Carlo 
simulation analysis for randomness evaluation. 
 
Figure 11. Validation of ID1 as a biomarker for responsiveness to PI3K-targeted therapies. 
(a) Apriori data mining process generated rules linking ID1 suppression with PI3K 
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chemosensitivity. (b) Sustained expression of p21WAF/Cip1 in Li-Fraumeni p53-deficient cells has 
tumor promoting ability (Galanos et al., 2016). Upon prolonged p21WAF/Cip1 expression the 
antitumor barrier of senescence is “bypassed”, generating “escaped” clones with aggressive and 
chemo-resistant features along with high ID1 expression levels (Galanos et al., 2016). 
Morphological features and senescence detection using SenTraGorTM, a novel staining marker 
(Evangelou et al., 2017), in induced and escaped Li-Fraumeni-p21WAF/Cip1 et-ON cells (Scale 
bar: 20 μm). (c) Combined PI3K inhibition and ID1 silencing decreased drug resistance of Li-
Fraumeni p21WAF/Cip1 escaped cells. Drug response curves for the PI3K inhibitors CAL-101 and 
ZSTK474 in the escaped Li-Fraumeni- p21WAF/Cip1 cells, before and after ID1 genetic silencing, 
and soft agar colony formation assay. Increased sensitivity is denoted by the left pointing red 
arrow showing leftward shift of dose response curve. ID1 siRNA targeting efficiency was 
verified by quantitative real time-RT-PCR and immunoblot analysis. (see details in 
Supplementary Materials section) DOX: doxocyclin, * denotes p < 0.05 
 
Figure 12. CDC6 overexpression as an indicator of resistance to MAPK pathway inhibitors. 
(a) The Apriori data mining process generated three rules linking CDC6 overexpression with 
resistance to MAPK (Mitogen-Activated Protein Kinase) inhibition. (b) Resistance to inhibitors 
is based on mutations that either render the MAPK pathway insensitive to treatment or reactivate 
alternative components of the signaling route bypassing the inhibitory block. (c) A CDC6-
inducible normal cellular model that recapitulates all stages of cancer development (Komseli et 
al., 2018). (d) Whole genome sequencing analysis in escaped versus OFF HBEC-CDC6 Tet-OFF 
cells (human bronchial epithelial cells) from three independent biological replicates 
demonstrated acquisition of p.R55T (c.G164C) mutation in exon 3 of MAP2K3. (e) Immunoblot 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
(IB) analysis of total and phosphorylated p38 MAPK in non-induced, one day induced and 
escaped HBEC-CDC6 Tet-OFF cells. (f) Histogram depicting the significantly increased 
resistance (p < 0.05) of escaped (Esc) from senescence HBEC-CDC6 cells, with high levels of 
CDC6, to the MEK1/2 inhibitor PD98059, relatively to the non-induced (OFF) cells with very 
low CDC6 levels (see IB in panel c). Non-induced (OFF) and Esc HBEC-CDC6 cells were 
incubated for 24h with 25μΜ PD98059. (see details in Supplementary Materials section) * 
denotes p  <  0.05 
 
Figure 13. Overlap of Association Rules with other frameworks. Overlap of Association 
Rules of the current study with GDSC, CCLE and CTRP. 
 
Figure 14. U-shaped curve demonstrating drug response or behaviour. 
 
Supplementary Figure legends 
Supplementary Figure 1. Description of full data set and summary of main data matrix. (a) 
Tissue of origin of the 1001 cell lines of the data-set. (b) Summary of the main data matrix 
containing tissue of origin, mutation status, gene expression, copy number variation and drug 
response information for the 1001 cancer cell lines (see “Data Availability” in Supportive 
material section). (c) Description of each data type used, including source, number of features 
and levels. 
 
Supplementary Figure 2. Relationships between metrics obtained through association rule 
mining. (a) Scatter plots presenting relation between confidence and support for 10,000 1-way 
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rules based on top support, confidence and lift. (b) Scatter plots presenting relation between 
confidence and support for 100,000 2-way rules based on top support, confidence and lift. 
 
Supplementary Figure 3. Representative output from the interactive Rshiny web 
application: https://compbio.nyumc.org/drugs/, confirming prior-knowledge on the 
Shieldin-PARPi association. 
 
Supplementary Figure 4. Validation of novel predicted gene-targets, identified by the ARM 
pipeline, that affect sensitivity or resistance to Doxorubicin.  
4a. Scheme and timeline of experiments. (a1) Experimental workflow of siRNA silencing and 
drug treatment. Timelines for (a2) dose response curve generation and (a3) soft agar colony 
formation following treatments with corresponding drugs and siRNAs (see details in 
Supplementary Materials section).  
4b. Experimental validation of novel predicted gene-targets, identified by the ARM pipeline, 
that affect sensitivity (2) or resistance (3) to Doxorubicin. (b1) Schematic representation of 
the gene selection algorithm. From the total of 1.326.251 found rules, 989.163 gene expression 
associated ones were employed.  (b2) Fold changes in IC50 levels, determined from dose 
response curves performed with MTT-assay (Supplementary File 3 - Doxorubicin_IC50), for 
the cell lines A549, H1299, MCF7 and Saos-2 treated with Doxorubicin in combination with 
silencing of MAGI3, POF1B, PDIA3, CD151 and NPTN (genes conferring sensitivity) relative to 
the IC50 levels of the cells when treated with the drug alone, and drug plus control siRNA (Ctl 
siRNA) (2i). Cell viability of A549, H1299, MCF7 and Saos-2 cells treated with: 1) Ctl siRNA, 2) 
POF1B, MAGI3, PDIA3, CD151 and NPTN siRNA, respectively, 3) Ctl siRNA plus Doxorubicin, 
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and 4) gene silencing plus Doxorubicin (2ii). (b3) Fold changes in IC50 levels, determined from 
dose response curves performed with MTT-assay (Supplementary File 3 - Doxorubicin_IC50), 
for the cell lines A549, H1299, MCF7 and Saos-2 treated with Doxorubicin in combination with 
silencing of TP53, CTCF, CCND3, ARHGDIB and ZCCHC7 (genes conferring resistance) 
relative to the IC50 levels of the cells when treated with the drug alone, and drug plus Ctl siRNA 
(3i). Cell viability of A549, H1299, MCF7 and Saos-2 cells treated with: 1) Ctl siRNA, 2) TP53, 
CTCF, CCND3, ARHGDIB ZCCHC7 siRNA, respectively, 3) Ctl siRNA plus Doxorubicin, and 4) 
gene silencing plus Doxorubicin (3ii). Note: H1299 and Saos-2 cell lines were not treated with 
si-TP53 because they are TP53-null.   
4c. Efficacy of genetic silencing in A549, H1299, MCF7 and Saos2 cells of genes conferring 
sensitivity (1) or resistance (2) to Doxorubicin treatment (see Supplementary Figure 4b). (1) 
Real time, quantitative (RT-)PCR analysis of POF1B, MAGI3, PDIA3, CD151 and NPTN mRNA 
expression levels before and after RNA silencing in A549, H1299, MCF7 and Saos-2 cells, and 
representative immunoblot analyses in A549 cells. (2) Real time, quantitative (RT-)PCR analysis 
of TP53, CTCF, CCND3, ARHGDIB and ZCCHC7 mRNA expression levels before and after 
RNA silencing in A549, H1299, MCF7 and Saos-2 cells, and representative immunoblot 
analyses in A549 cells. Note: H1299 and Saos-2 cell lines were not treated with si-TP53 because 
they are TP53-null.  
4d. Doxorubicin (Dox) dose response curves in the A549, NCI-H1299, MCF7 and Saos-2 
cells. (1) Dose response curves in the A549, NCI-H1299, MCF7 and Saos-2 cell lines after 
treatment with Doxorubicin (Dox) alone or with control siRNAs cells to estimate the 
corresponding IC50 values. (2) Representative confirmatory dose response curves after silencing 
each gene (MAGI3, POF1B, PDIA3, CD151, NPTN) that confers sensitivity in selected cell lines. 
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Increased sensitivity is denoted by the left pointing red arrow showing leftward shift of dose 
response curve. (3) Representative confirmatory dose response curves after silencing each gene 
(TP53, CTCF, CCND3, ARHBD1B and ZCCHC7) that confers resistance in selected cell lines. 
Increased resistance is depicted by the right pointing red arrow showing rightward shift of dose 
response curve. Note: H1299 and Saos-2 cell lines were not treated with si-TP53 because they 
are TP53-null.  
4e. Soft agar colony formation assays in the A549, NCI-H1299, MCF7 and Saos-2 cell lines 
after treatment with Doxorubicin (Dox) alone or with siRNAs against (1) genes conferring 
sensitivity MAGI3, POF1B, PDIA3, CD151, NPTN, (see Supplementary Figure 4b) and (2) 
genes conferring resistance TP53, CTCF, CCND3, ARHBD1B, ZCCHC7 (see Supplementary 
Figure 4b). Note: H1299 and Saos-2 cell lines were not treated with si-TP53 because they are 
TP53-null. * denotes p < 0.05, ctl-siRNA: control siRNA (see details in Supplementary 
Materials section) 
 
Supplementary Figure 5. (a.) CDC6 overexpression is a poor prognostic factor in common 
human malignancies. Log-rank (Mantel-Cox) survival analyses, with Bonferroni correction, 
were performed to assess the association of CDC6 overexpression with survival of patients in 
four common human malignancies (lung, pancreatic and prostate adenocarcinomas, along with 
breast carcinomas). CDC6 mRNA expression levels were obtained from mRNA microarrays. 
CDC6 mRNA expression levels and patients’ survival status were extracted from METABRIC. 
(b.) The R55T mutation of MAP2K3. As the R55T mutation of MAP2K3 was also observed in 
colon cancer we investigated its possible role in the functionality of the particular kinase. We 
attempted to create a theoretical model by using several available crystal structures of 
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homologous MAPK kinases (MAPKKs) as templates. However, in all cases R55 was 
unambiguously mapped on a disordered region of the kinase N-terminal lobe preceding β sheet 1. 
As a result, the mutation site and its precise topology could not be inspected within the context of 
a consistent homology model. Yet, there are specific indications that the positioning of R55 
within the N-terminal region of MAP2K3 may be of pivotal role to the functionality of the 
particular kinase as a regulator of signal transduction cascades. Indeed, a number of short linear 
motifs have been associated in the past with regulatory properties for MAPK kinases. Such 
patterns have been reported to be involved in a diverse range of functions including both 
inactivation through the formation of autoinhibitory dimmers, like in the case of the closely 
related MAP2K6 or, conversely, the establishment of protein-protein interactions that can greatly 
increase affinity for downstream kinases, therefore facilitating more efficient phosphorylation 
and, consequently, ensuring higher activation levels as well as selectivity over isoforms (Enslen 
et al., 2000; Chang et al., 2002; Kragelj et al., 2015; Min et al., 2009). Those regulatory N-
terminal sequence patterns include the relatively infrequent 'arginine stacks' (Min et al., 2009) 
and several categories of specificity-determining docking sites of downstream target proteins (D 
motifs) (Enslen et al., 2000). They are comprised in most of the described cases by adjacent 
basic residues and, as already mentioned, they have been found to drastically affect both the 
activity of the specific kinases as well as the activation state of their downstream targets 
(Holland & Cooper, 1999). For example, activation by different MAPKKs of specific isoforms 
of p38 kinase is strongly dependent upon the presence of a particular 18-residue long docking 
motif on the MAPKK N-terminal domain that confers the desired selectivity over the untargeted 
p38 isoforms (Enslen et al., 2000). As a result, it is reasonable to expect that the R55T mutation 
on MAP2K3 would possibly have a non-negligible effect on the overall functionality of the 
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enzyme, either with respect to its self-regulatory dynamics or regarding its activity as an effector 
that regulates downstream proteins such as p38. Although R55 could not be identified as a 
component of the docking sites of MAP2K6 and MAP2K3β (Enslen et al., 2000; Chang et al., 
2002) or on the arginine stack motif of MAP2K6 (Min et al., 2009), the possibility that it 
comprises an essential part of a regulatory domain cannot be ruled out. Indeed, its spatial 
proximity with structural determinants on the N-terminal region that are important for kinase 
function such as the active site and the Glycine-rich loop could possibly justify a significant 
contribution of the particular residue to the stabilization and subsequent dynamics of the kinase. 
Whereas additional studies are needed to further clarify the structural and dynamical role of the 
effect the aforementioned mutation has on MAPK signaling, this finding could offer a starting 
point for introducing a hypothesis that the observed over-activation of p38 kinase (Figure 12e) 
can be approached as a regulatory perturbation of MAP2K3 caused by the altered dynamics of 
the R55T mutant that triggers aberrant activation of its downstream kinase. 
(c.) Dose response curves for the MEK1/2 inhibitor PD98059 in the HBEC-CDC6 Tet-ON 
cellular system. Rightward shift in dose response curve (red arrow) in escaped relative to non-
induced HBEC-CDC6 Tet-ON cells (Komseli et al., 2018), denoting resistance of these 
malignant counterparts to the inhibitory effect of the MEK1/2 inhibitor PD98059. * denotes p < 
0.05 (see details in Supplementary Materials section) 
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Table 1. Terminology description and further reading. 
 
Term Description Reference 
Algorithm 
Set of instructions (performed in a stepwise manner) used to solve a class of problems or perform a 
computation, in the fields of mathematics and computer science 
James. et al. (2013) Springer, ISBN 978-1-4614-7138-7 
 
Algorithm parameters 
 
The parameters set for an algorithm like k (number of clusters) or the input data 
Nelder and Wedderburn. (1972) Journal of the Royal Statistical 
Society. Series A, 135: 370-384. 
 
Artificial intelligence 
 
The scientific domain aiming to give the computer systems the ability of learning, reasoning and self-
correction 
Brookshear J.G. (2008) Computer Science: An Overview. 
Addison-Wesley Publishing Company USA ISBN: 
9780321524034 
 
Batch effect removal 
 
The removal of technical variations from  data that introduce systematic bias between groups of 
examined samples 
Luo, et al. (2010) Pharmacogenomics J. 10: 278–291. 
 
Bayesian inference 
 
A statistical method that updates the probability for a hypothesis as more data become available to the 
model 
van de Schoot, et al. (2014). Child Dev. 85: 842–860 
 
Bias 
 
How different is the correct value we originally wanted to predict with our model, from the average 
prediction of our model 
https://towardsdatascience.com/understanding-the-bias-variance-
tradeoff-165e6942b229 
 
Big data 
 
Collection of very large information used in computational analyses to reveal patterns, trends, and 
associations (> 1TB information) 
Kleppmann M. (2017) Designing Data-Intensive Applications: 
The Big Ideas Behind Reliable, Scalable and Maintainable 
Systems, ISBN-13: 978-1449373320 
 
Classification 
 
Is a supervised learning process based on an algorithm that  categorizes the output into a limited set of 
values 
James, et al. (2013) Springer, ISBN 978-1-4614-7138-7 
 
Clustering 
 
Unsupervised machine learning process used to group a set of objects, based on similarity (see also 
Table 2) 
Trilla-Fuertes, et al. (2019) BMC Cancer. 19: 636 
 
Computer science 
 
Multidisciplinary field that studies computers and computational concepts 
Brookshear JG (2008) Computer Science: An Overview. 
Addison-Wesley Publishing Company USA ISBN: 
9780321524034 
 
Cost function 
 
A measure of how badly a machine learning model behaves 
https://towardsdatascience.com/machine-learning-fundamentals-
via-linear-regression-41a5d11f5220 
 
Data mining 
 
Process of unveiling hidden patterns from enormous data sets using methods of statistics, database 
systems and machine learning 
Bishop, C.M. (2006) Pattern Recognition and Machine Learning, 
Springer, ISBN 978-0-387-31073-2 
 
Feature selection 
 
The process in statistics and machine learning in which a subset of relevant features/variables  is 
selected in order to be used in the model construction 
James, et al. (2013) Springer, ISBN 978-1-4614-7138-7 
 
General linear models 
 
Under this term are any statistical linear models in the form of y = ax+b (see also Table 2), where 
x=input, y=output 
Nelder and Wedderburn. (1972) Journal of the Royal Statistical 
Society. Series A, 135, 370-384. 
 
Imputation 
 
Replacing of missing data with substituted values James, et al. (2013) Springer, ISBN 978-1-4614-7138-7 
Independent evaluation Test, after training, of a candidate model to accurately predict response on unseen settings 
Bishop, C.M. (2006) Pattern Recognition and Machine Learning, 
Springer, ISBN 978-0-387-31073-2 
Iterative rule-based approach 
Rule based process that starts from all the samples in the cohort proceeding to a subset of samples and is 
executed until there are no features fulfilling the requirements to further divide the subset of samples 
into groups 
Chen et al. (2015) Cancer Res 75: 2987–98. 
 
Kernelized regression 
 
A non-parametric technique in statistics to estimate the conditional expectation of a random variable 
Henderson and Parmeter. (2015). Applied Nonparametric 
Econometrics. Cambridge Core 
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k-fold cross-validation (KF-CV)* 
A nested cross-validation technique where the dataset is split into k groups with the k-1 groups used as 
the training set and the remaining group as the test set 
Stone M. (1974) J. Royal Stat Soc 36: 111–147 
 
Machine learning 
 
Scientific discipline that uses algorithms and statistical tools to perform tasks without instructions but 
based on patterns and deductions 
Bishop, C.M. (2006) Pattern Recognition and Machine Learning, 
Springer, ISBN 978-0-387-31073-2 
 
Matching 
 
The establishment of a link between separate data records that are related to the same entity 
https://liliendahl.com/2018/11/28/data-matching-machine-
learning-and-artificial-intelligence/ 
 
Metrics of performance 
 
The metrics used in order to evaluate the performance of a machine learning model (AUC, Accuracy 
etc) 
Bishop, C.M. (2006) Pattern Recognition and Machine Learning, 
Springer, ISBN 978-0-387-31073-2 
 
Model fit 
 
The process of training a model to accurately represent the data trend James, et al. (2013) Springer, ISBN 978-1-4614-7138-7 
 
Model generalisation 
 
When a trained machine learning model maintains its predictive power in blind datasets. 
Dietterich, T. (1995) ACM Computing Surveys (CSUR) 27: 326-
327 
 
Multi-task learning 
 
Concurrent solving of multiple tasks with shared use of commonalities and differences across these 
tasks 
Ruder, S. (2017) arXiv, 1706.05098. 
 
Multi-view learning 
 
The integration of data from multiple sources  Zhao, et al. (2017). Inf. Fusion 38(C): 43–54. 
 
Network-based data representations 
 
The representation of data via graphs, whose vertices represent data points (entities) and the edges 
represent relationships between pairs of those data points 
Wang, et al. (2014) Similarity network fusion for aggregating 
data types on a genomic scale. Nat Methods 11: 333–7. 
 
Normalization 
 
Is a data pre-processing technique, the goal of which is to change the values of numeric columns in the 
dataset to a common scale, without distorting differences in the ranges of values with the goal of 
integration for model training and inference. 
Milligan and Cooper. (1988) Journal of Classification, 5: 181–
204. 
 
Overfitting/ Overtraining 
 
When a model implements noise and fluctuations from the training set as real data for learning.  
Dietterich, T. (1995) ACM Computing Surveys (CSUR) 27: 326-
327 
Pattern recognition A procedure of recognizing patterns and regularities in data processed in machine learning. 
Bishop, C. M. (2006), Pattern Recognition and Machine 
Learning, Springer, ISBN 978-0-387-31073-2 
 
Regularization 
 
Process based on penalization that prevents the model becoming too complex and flexible, in order to 
avoid overfitting 
Dietterich, T. (1995) ACM Computing Surveys (CSUR) 27: 326-
327 
Sample stratification  Sampling from a data set which can be separated into non-overlapping subgroups. 
https://archive.is/20131013132818/http://nestor.coventry.ac.uk/~
nhunt/meths/strati.html 
 
Supervised 
 
Machine learning category in which the algorithm receives as input labeled data points (see also Table 
2) 
Libbrecht and Noble. (2015) Nat Rev Genet 16: 321–332 
 
Testing phase 
 
Part of the machine learning process where the algorithm performance after training is evaluated on a 
new data set not used in the training phase 
Libbrecht and Noble. (2015) Nat Rev Genet 16: 321–332 
 
Training phase 
 
Part of the machine learning process where the algorithm is provided with a large data set, processes it 
and builds a model 
Libbrecht and Noble. (2015) Nat Rev Genet 16: 321–332 
 
Transfer learning 
 
The term has dual different uses: i) in ensemble learning methods, it involves taking the results from 
one model to improve the results of another 
ii) inclusion of more than one features in training data, while only one of these features is used in testing 
data 
Weiss et al. (2016) J Big Data, 3: 9. 
 
Underfitting/ Undertraining 
 
When a model can neither learn the training data nor generalize to new data. 
Dietterich, T. (1995) ACM Computing Surveys (CSUR) 27: 326-
327 
 
Unsupervised 
 
Machine learning category in which the algorithm receives as input  unlabeled data points (see also 
Table 2) 
Libbrecht and Noble. (2015) Nat Rev Genet 16: 321–332 
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Variance 
 
Is an indication of how much our model can be generalized on new data other than the ones it was 
trained on 
https://towardsdatascience.com/understanding-the-bias-variance-
tradeoff-165e6942b229 
 
Weighted model 
 
Methods used in MCDA* applications for evaluating a number of alternatives in terms of a number of 
decision criteria 
Triantaphyllou, E. (2000). Multi-criteria Decision-Making 
Methods - A Comparative Study Springer US. ISBN 978-1-4757-
3157-6 
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Table 2. A highlight of machine learning algorithms used in drug response prediction. 
 
Type of Algorithm Algorithm Name Brief Description Pros Cons References 
 
 
Supervised – 
Linear 
 
 
 
Linear Regression 
 
 
Is the statistical method that assumes the relationship 
between a single predictor value X and a quantitative 
response Y is linear 
 
 
- Very simple 
- Efficient solution for most 
simple problems 
- Only models linear 
relationships 
- Sensitive to over-fitting 
when number of 
features >> number of 
samples 
James et al., (2013) 
Springer ISBN 978-1-
4614-7138-7 
Support Vector 
Machines (SVMs)* 
 
 
Is a classification algorithm that has an input of 
vectors that are non-linearly mapped to a very high 
dimensional feature space, and finds the optimal 
separating hyperplane for those data 
 
- Convex Optimization 
ensures that the solution 
reached is the global 
minimum. 
- Very fast 
- Cannot model non-
linear systems 
- Cannot handle many 
features and therefore 
needs extensive feature 
engineering as a pre-
processing step 
Cortes and Vapnik. 
(1995) Machine 
Learning. 20: 273–297 
 
 
Supervised – 
Linear-Penalisation 
 
 
 
Ridge Regression 
 
Is a statistical method close to least squares that uses 
penalisation when finding coefficient estimates. This 
method keeps all the initial predictors in the final 
model 
- It avoids overfitting and can 
be applied even when number 
of features is larger than 
number of data 
- It does not lose information 
like Lasso because it does not 
completely eliminate the 
features 
- Usually delivers better 
performance than the Lasso 
when highly correlated 
features are present 
 
- Cannot be used as a 
feature selection tool 
 
James et al., (2013) 
Springer ISBN 978-1-
4614-7138-7 
Lasso regression 
 
In contrast to ridge regression, lasso yields “sparse” 
models that include only a subset of the initial values. 
 
- It avoids overfitting and can 
be applied even when number 
of features is larger than 
number of data 
- It can do feature selection 
- Very fast training and 
inference 
 
- Unstable feature 
selection process. On 
different bootstrapped 
data, the selected features 
can vary significantly. 
- Feature selection is not 
easily interpretable. 
 
James et al., (2013) 
Springer ISBN 978-1-
4614-7138-7 
Elastic Net 
 
The elastic net is a regularized regression method that 
combines the penalisation used in the lasso and the 
ridge regression methods 
- All the advantages of  Lasso 
and Ridge 
- Complex model 
hyperparameter 
optimisation 
Hui and Hastie. (2005) 
Journal of the Royal 
Statistical Society, Series 
B: 301–320. 
 
 
Supervised – 
Non linear 
Naive Bayes 
Is a probabilistic machine learning classifier based on 
Bayes theorem 
- Computationally efficient 
-Simple to implement 
- Works equally well with 
both linear and non-linear 
data 
- Relies on the 
assumption that features 
are independent and will 
produce poor results if 
this assumption is false 
Maron, M.E. (1961) 
Journal of the ACM. 8: 
404–417. 
Decision Trees 
 
Is a machine learning tool that uses a graphical 
representation of events/decisions composed of nodes, 
branches and endpoints. 
 
- Easily interpretable. 
- Especially good in handling 
categorical features 
- Computationally efficient 
 
- Prone to overfitting 
 
Breiman, et al. Olshen 
(1984) Chapman and 
Hall/CRC ISBN 
9780412048418 - CAT# 
C4841 
 
Neural Networks 
Is a system inspired by biological neural networks. It 
consists of an input layer, a hidden layer and an 
output layer. Each layer contains nodes called neurons 
that are fully connected to the neurons of the next 
layer. Neurons transmit signals through their 
connections just like the biological paradigm. 
- Can capture complex non-
linear relationships between 
features 
- No feature selection or 
feature engineering is 
required. This automatically 
happens in the hidden layer. 
-Tendency to overfit 
unless techniques such as 
dropout are used 
-It requires large amount 
of data to reach 
maximum performance 
-Computationally 
expensive training 
McCulloch and Pitts. 
(1943). Bulletin of 
Mathematical 
Biophysics. 5: 115–133. 
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-multi-dimensional 
feature relationships 
captured in the hidden 
layers is not interpretable 
Deep Neural 
Networks 
Is like the Artificial Neural Network, the only 
difference being that there are multiple fully 
connected hidden layers 
- Same as Neural Networks 
only much more efficient due 
to higher number of hidden 
layers 
-Same as Neural 
Networks only much 
more computationally 
expensive training 
Hinton, G.E. (2007) 
Trends in Cognitive 
Sciences. 11: 428–434. 
Supervised – 
Non linear-Ensemble 
Random Forests 
 
Is an ensemble learning method that combines a 
multitude of single fully grown decision trees (low 
bias, high variance) with randomly selected subsets of 
features to calculate the final result 
- Top predictive performance 
with minimal model tuning 
- Provides a robust feature 
selection importance metric 
- They do not over-fit 
- Computationally 
expensive training and 
inference 
- Low interpretability of 
the ensemble model 
 
Breiman, L. (2001) 
Machine Learning 45: 5–
32. 
Gradient Boosting 
Machines (GBMs)* 
 
 
Is an ensemble learning method that combines a 
multitude of weak learners - shallow trees with high 
bias and low variance that are increasingly focused on 
hard examples in contrast to the fully grown decision 
trees used in random forests 
 
- Top predictive performance 
equivalent or superior to 
Random Forests 
- Resistant to over-fitting 
- Same as random forests 
plus model instability 
hence small changes in 
the training or feature set 
can create models of 
radically different 
performance 
Friedman, J.H. (2001) 
The Annals of Statistics 
29: 1189-1232. 
Unsupervised - 
Clustering 
 
k-means 
 
Is a hard clustering method aiming to assign n data 
points to k clusters, using the mean and resulting to 
partitioning of the space into Voronoi cells. 
 
- Very computationally 
efficient when it comes to big 
data 
- Works well with non-linear 
data 
 
- k needs to arbitrarily be 
defined 
- Unstable in the sense 
that can create different 
representations based on 
different initializations 
Nidheesh, et al. (2017) 
Comput Biol Med 91: 
213-221; 
Trilla-Fuertes et al. 
(2019) BMC Cancer. 19: 
636 
Hierarchical 
clustering 
Is a method that seeks to build hierarchy clusters 
either through a bottom-up (Agglomerative) or a top-
down (Divisive) approach. 
- The tree-like structure is 
very informative 
- Results are very stable and 
independent of different 
intialisations 
- Quite computationally 
demanding 
- Cannot readily identify 
distinct groups 
Lior and Maimon. (2005) 
Springer US, 321-352; 
Pritchard et al. (2013) 
Mol Biosyst 9: 1604-19. 
Unsupervised - 
Dimensionality 
reduction 
 
 
PCA (Principal 
Component 
Analysis)* 
 
Is a linear statistical procedure that converts a set of 
observations into a set of linearly uncorrelated 
variables called principal components 
- Reduction in size of data. 
- It creates totally 
uncorrelated components 
 
- Not computationally 
efficient when handling 
big data 
- Works best when 
original features are 
linearly correlated 
Pearson, K. (1901). 
Philosophical Magazine 
2: 559–572. 
 
t-SNE 
(t-distributed 
Stochastic 
Neighbor 
Embedding)* 
 
Is a machine learning algorithm for non-linear 
dimensionality reduction and visualisation 
- Works well when features 
are non-linearly correlated 
- Produces superior 
visualisations to PCA 
- Not computationally 
efficient when handling 
big data 
- Underperforms unless 
data is strongly non-
linear 
 
van der Maaten and  
Hinton (2008) Journal of 
Machine Learning 
Research. 9: 2579–2605 
Deep Autoencoders 
Is an unsupervised deep learning network that applies 
backpropagation for training with the goal to 
reconstruct its input 
Same as deep neural networks 
Same as deep neural 
networks 
Hinton and Zemel. 
(1994). Advances in 
neural information 
processing systems pp: 3-
10; Rampášek L, et al. 
(2019) Bioinformatics, 
pii: btz158. 
Unsupervised - Rule 
based 
 
 
Association Rule 
Mining 
 
 
Is a statistical procedure to identify association 
patterns in data and express them in the form of rules 
- Efficient algorithm, ideal for 
big-data handling 
- Exhaustive algorithm that 
discovers all associations in a 
data-set 
- Generates easy to interpret 
rules 
- Can model complex multi-
way relationships given a 
data-set of adequate size 
- Multi measures of 
significance 
- If data-set is small the 
algorithm tends to 
generate false 
associations 
- Can only model AND 
logical associations. 
Cannot represent rules 
containing various logic 
handlers such as OR, 
NOT, XOR 
 
 
Agrawal et al (1993). 
Proceedings of the 1993 
ACM SIGMOD 
international conference 
on Management of data,  
pp. 207-216 
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Table 3. Publicly available repository panels containing big-data for building machine learning and data mining 
frameworks. 
Features\Resource NCI-DREAM 
AstraZeneca-Sanger 
DREAM 
NCI-60 GDSC CCLE TCGA/TCPA 
 
Sample type 
 
53 breast cancer cell lines 85 cancer cell lines 
59 cell lines from 9 tissue 
types 
1124 cell lines from 29 
tissue types 
>1000 cell lines from 36 
types of cancer 
~ 11,000 patient tumors from 
33 tissue types 
Number of 
compounds: 
28 compounds 
910 pairwise 
combinations of 118 
drugs 
>1,500 265 24 - 
 
Main omics data sets 
 
Mut, CNV, Meth, GE, PR Mut, CNV, Meth, GE Mut, CNV, GE, Meth, PR Mut, CNV, Meth, GE Mut, CNV, Meth, GE 
Mut, CNV, GE, Meth, PR, 
Hist 
 
Number of cancers 
 
1 6 9 55 36 33 
Reference 
Costello et al. (2014) Nat 
Biotechnol 32: 1202. 
Menden et al. (2019) Nat 
Commun 10: 2674 
Shoemaker RH. (2006) 
Nat Rev Cancer 6: 813. 
 
Garnett et al. (2012) 
Nature 483: 570. 
 
Barretina et al. (2012) 
Nature 483: 603. 
Weinstein et al. (2013) Nat 
Genet 45: 1113/ 
Li et al. (2013) Nat Methods 
10: 1046. 
Website 
https://www.synapse.org/#
!Synapse:syn2785778/wiki
/70252 
https://www.synapse.org/
DrugCombinationChallen
ge 
discover.nci.nih.gov/cell
miner/ 
http://www.cancerrxgen
e.org/ 
http://www.broadinstitute
.org/ccle 
http://cancergenome.nih.gov/  
http://tcpaportal.org/tcpa/ 
 
 
Mut: gene Mutation; CNV: gene Copy Number Variation; GE: Gene Expression; Meth: DNA Methylation, PR: Protein Expression, Hist: 
Histopathological images 
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Table 4. Performance metrics of machine learning frameworks. 
 
Model types Performance measure Type of measure 
Regression 
models 
R² 
R-squared is a statistical measure that represents the proportion of 
the variance for a dependent variable that is explained by an 
independent variable or variables in the regression model under 
evaluation. 
 
Adjusted R² 
 
 
Similar to R² but with a penalty for increasing model complexity 
 
Root Mean Square Error (RMSE)* 
The Root Mean Squared Error measures the square root of the 
average of the squared difference between the predictions and the 
ground truth. 
 
Mean Absolute Error 
 
The Mean Absolute Error measures the average of the absolute 
difference between each ground truth and the predictions. 
F-Test 
The F-Test compares the model to be evaluated against a model 
with no variables. The null hypothesis is that the model with no 
variables performs just as good as the model with the variables. 
Classification 
models 
 
Log Loss (Logarithmic Loss or Cross 
Entropy Loss) 
 
Penalizes classifiers during prediction. It is maximal for false 
prediction classification. 
 
True Positive (TP)* 
 
Equivalent with hit 
True Negative (TN)* Equivalent with correct rejection 
False Positive (FP)* Equivalent with false alarm (Type I error) 
False Negative (FN)* Equivalent with miss (Type II error) 
Sensitivity, recall, hit rate, or true 
positive rate (TPR)* 
True Positives over all Positives 
Specificity, selectivity or true negative 
rate (TNR)* 
True Negatives over all Negatives 
 
Precision or positive predictive value 
(PPV)* 
True Positives over True Positives plus False Positives 
Negative predictive value (NPV)* True Negatives over True Negatives plus False Negatives 
Miss rate or false negative rate (FNR)* False Negatives over all Positives 
 
Fall-out or false positive rate (FPR)* False Positives over all Negatives 
 
False discovery rate (FDR) 
 
False positives over False Positives plus True Positives 
 
False omission rate (FOR) 
 
False Negatives over False Negatives plus True Negatives 
Accuracy (ACC) 
True Positives plus True Negatives over  all Positives plus all 
Negatives 
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F1 Score The harmonic mean of precision and sensitivity 
Youden’s Index 
A single statistic that captures the performance of a dichotomous 
diagnostic test 
Area under the ROC curve (AUC) 
The ROC curve is plotted with TPR against the FPR where TPR is 
on the y-axis and FPR is on the x-axis. AUC is the area under this 
curve. AUC 0.5 indicates a random model whose performance is 
equivalent to chance. AUC 1 indicates the perfect predictive model 
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Table 5. Highlights of machine learning applications in oncology in chronological order 
 
Year Reference Model applied Training set Testing set Outcome 
2011 
Gillet et al. (2011) Proc Natl Acad Sci 
USA 108: 18708–13.  
BRB-ArrayTools for classification of 
tumor types and Hierarchical 
clustering analysis 
NCI-60 cancer cell line panel Primary tumors of different origin 
Tendency of cell lines of different 
anatomical origin to resemble 
each other, rather to reflect their 
origin 
2013 
Daemen et al. (2013) Genome Biol 
14: R110.  
1) Weighted least squares support 
vector machine (LS-SVM) and 2) 
Random Forests (RF) 
 
Breast cancer cell lines 
 
TCGA breast tumors for which 
expression (Exp), copy number 
(CNV) and methylation (Meth) 
measurements were available 
AUC based sensitivity prediction 
2013 
Niepel et al. (2013) Sci Signal 6: 
ra84.  
Partial least-squares regression to 
simulate signaling networks 
activation profile 
 
NCI-ICBP43 breast cancer cell 
line collection 
 
Breast cancer cell lines Prediction of drug sensitivity 
2103 
Byers et al, (2013) Clin Cancer Res 
191: 279–90.  
Hierarchical clustering and principal 
component 
Analysis (PCA) 
Non–small cell lung carcinoma 
(NSCLC) cell lines 
 
i) non–small cell lung carcinoma 
(NSCLC) cell lines 
ii) patients treated in the Biomarker-
Integrated Approaches of Targeted 
Therapy for Lung Cancer Elimination 
(BATTLE) study. 
EMT signature that predicts drug 
resistance to EGFR and PI3K/Akt 
inhibitors 
2014 
Geeleher et al. (2014) Genome Biol 
15: R47.  
Ridge Regression 
Cancer Genome Project (CGP) 
cell lines 
 
i) Docetaxel treated breast cancer 
patients 
ii) Paclitaxel treated breast cancer 
patients 
iii) Bortezomib treated myeloma 
iv) Erlotinib treated NSCLC 
Sensitivity versus resistance 
prediction 
2014 
Guinney et al. (2014) Clin Cancer Res 
20: 265–72. 
Penalized ElasticNet regression 
Fresh-frozen colorectal cancer 
tissues analyzed for K-ras 
(codons 12 and 13) mutations 
 
i) Cetuximab response: mouse 
xenografts and patients 
ii) MAP–ERK kinase (MEK) 
inhibition: cell lines and mouse 
xenografts 
Prediction response to anti-EGFR 
agents and MEK inhibitors based 
on RAS phenotype 
2014 
Tran et al. (2014) BMC Syst Biol 8: 
74. 
ElasticNet regression combined with 
logarithmic transformation of the data 
Kinase inhibitor treated cell 
lines 
Experimental validation 
 
Identification of specific kinases 
linked to drug response of a given 
cell line 
 
 
 
2014 
 
Liang et al. (2014) Int  J Mol Sci 15: 
11220–33.  
 
A linear model was applied for 
continuous covariates along with 
ANOVA test for categorical 
covariates 
 
Neuroblastoma cell lines and 
patients 
 
 
Neuroblastoma patients 
 
REST-driven transcriptional 
signature associated with 
neuroblastoma drug sensitivity 
 
2014 
Costello et al. (2014) Nat Biotechnol 
32: 1202-12. 
 
Wining model: Bayesian efficient 
multiple kernel learning (BEMKL) 
method  
 
Breast cancer cell lines Cell lines 
Community effort to define the 
state-of-the-art in drug response 
prediction from ‘omic’ data 
2015 
Falgreen et al. (2015) BMC Cancer 
15: 235. 
 
Penalized ElasticNet regression 
combined with Lasso and Ridge 
Regression 
 
Combined human B-cell 
cancer cell lines (HBCCL) 
with published CGP gene 
expression datasets 
Diffuse large B-cell lymphoma 
(DLBCL) patients treated with CHO: 
cyclophosphamide (C), doxorubicin 
(H), and vincristine (O) 
Generate resistance gene 
signatures (REGS) for predicting 
sensitivity or resistance 
2015 
Chen et al. (2015) Cancer Res 75: 
2987–98. 
PSFinder: an iterative rule–based 
unsupervised approach 
TCGA derived high-grade 
serous ovarian cancer (HGS-
OvCa) with platinum–taxane 
therapy 
Separate TCGA derived high-grade 
serous ovarian cancer (HGS-OvCa) 
with platinum–taxane therapy 
Classification into poor versus 
positive survival outcome 
2015 Fey et al. (2015) Sci Signal 8: ra130. 
Rule based modeling employing 
ordinary differential equations 
(ODEs) to simulate reactions and 
states of the JNK pathway 
i) Neuroblastoma 
cells lines 
ii) Neuroblastoma patients 
 
i) Neuroblastoma cells lines 
ii) Neuroblastoma patients 
iii) Zebrafish neuroblastoma model 
 
Survival prediction based on 
activation status of JNK pathway 
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2015 
Pereira et al. (2015) PLoS One 10: 
e0145754. 
 
Log-binomial models combined with 
logistic regression models 
 
Patients with gynecologic 
malignancies 
Patients with gynecologic 
malignancies 
Circulating tumor DNA (ctDNA) 
as a post-treatment survival 
biomarker 
2015 
Zheng et al. (2015) 
Pharmacogenomics J 15: 135–43. 
 
BRB-arrayTools to perform 
regression analysis 
 
Colorectal cancer cell lines 
with available gene expression 
profiles 
Colorectal cancer clinical cohorts 
Contribution of drug resistance-
related genes to patient survival 
2019 
Menden et al. (2019) Nat Commun 
10: 2674 
Ensemble models Cancer cell lines Cancer cell lines and PDX models 
Community effort to define 
computational strategies for 
predicting synergistic drug pairs 
and biomarkers 
2019 
Chiu et al. (2019) BMC Med 
Genomics 31: 12:18. 
DLNN 
 
Cancer cell lines from CCLE 
& GDSC, clinical samples 
from TCGA 
clinical samples from TCGA (33 
cancer types) 
Drug response prediction 
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Table 6. Potential mechanism of action following genes silencing that confers sensitivity to 
doxorubicin treatment. 
Gene Function Mechanism affecting 
sensitivity 
Reference 
 
 
 
 
POFB1 
(Premature 
Ovarian Failure 
Protein 1B) 
 
 
 
 
Plays a key role in the 
organization of 
epithelial monolayers 
by regulating the actin 
cytoskeleton. 
 
POF1B loss:  
1. Disrupts binding of 
non-muscle actin 
filaments. 
2. Abolishes tight 
junction localization. 
Thus, potentially 
enhances Doxorubicin 
mediated cytoskeleton 
re-organization related to 
cell shrinkage, 
detachment and 
apoptosis. Consequently 
cells develop increased 
sensitivity to 
Doxorubicin requiring 
lower IC50 values of the 
drug. 
 
 
 
 
 
Padovano V et al, J 
Cell Sci 2011 
Lacombe A et al, 
AJHG 2006  
Crespi A et al, J 
Invest Dermatol 2014 
Lee SJ et al, BMB 
Rep 2017  
 
 
 
 
 
 
 
Gene Function Mechanism affecting 
sensitivity 
Reference 
    
+ Doxorubicin (IC50) siPOF1B+ Doxorubicin (↓ IC50)
Enhanced cell death
non-muscle actin filaments
tight junctions
POF1B
nucleus
1.
2. 3.
4.
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MAGI3 
(Membrane-
Associated 
Guanylate Kinase) 
Acts as a scaffolding 
protein at cell-cell 
junctions, thereby 
regulating various 
cellular and signaling 
processes. Modulate 
the activity of ERK and 
AKT1 pathways. 
 
Loss of MAGI3 
expression disrupts 
activation of the 
PI3K/AKT and/or ERK 
pathways assisting 
Doxorubicin treatment 
effect (lower IC50 value 
for Doxorubicin 
treatment). 
Zhang H et al, Cell 
Signal 2007  
Abrams SL et al, Cell 
Cycle 2010  
Wang Y et al, 
Neoplasma 2015  
Wu Y et al, J Biol 
Chem. 2000  
 
 
 
 
siMAGI3 + Doxorubicin (↓ IC50)
cell junctions
MAGI3
nucleus
PI3K/AKT
ERK
PI3K/AKT
ERK
PI3K/AKT
ERK
PI3K/AKT
ERK activation
Decreased
cell survival
Doxorubicin (IC50)
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Gene Function Mechanism affecting 
sensitivity 
Reference 
 
 
 
PDIA3 
(ERp57/PDIA3: 
Protein disulfide 
isomerase family) 
 
A phosphatidylinositol 
4,5-bisphosphate 
phosphodiesterase type I 
(phospholipase C-alpha). 
Catalyzes the 
rearrangement of -S-S- 
bonds in proteins. Acts in 
concert with calreticulin 
and calnexin in the 
folding of glycoproteins 
destinated to the plasma 
membrane or to be 
secreted.  
 
 
 
Functions as a hub 
integrating signals that 
mediate metastasis. Its 
silencing inhibits cell 
proliferation and 
increases sensitivity to 
ionizing radiation and 
chemotherapeutics. 
Therefore, cells develop 
increased sensitivity to 
Doxorubicin requiring 
lower IC50 values of the 
drug. 
 
 
 
Santana-Codina N 
et al, Mol Cell 
Proteom 2013 
Hussmann M et al, 
Oncotarget 2015 
Su BB et al, J Surg 
Res 2016  
 
 
 
 
siPDI 3 + Doxorubicin (↓ IC50) 
PDIA3
nucleus
signaling
Decreased
metastasis
Metastasis
Doxorubicin (IC50)
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Gene Function Mechanism affecting 
sensitivity 
Reference 
 
 
 
CD151 
(Tetraspanin-24) 
 
CD151 is a cell surface 
glycoprotein that 
associates strongly with 
the laminin-binding 
integrins (α3β1, α6β1 
and α6β4), growth 
factors and matrix 
metalloproteinases. It is 
involved in epithelial 
cell–cell adhesion. 
 
 
Inhibition of CD151 
affects integrin-
mediated cell adhesion 
and signaling, resulting 
in sensitivity to 
Doxorubicin treatment 
(lower IC50 value for 
Doxorubicin treatment). 
Targeting CD151 
inhibits metastasis by 
blocking cell motility. 
 
 
Yamada M et al, 
FEBS J 2008  
Haeuw J-F et al, 
Biochem Soc Trans 
2011 
Lovitt CJ et al, BMC 
Cancer 2018  
Liu T et al, Mol Cell 
Biochem 2015  
 
 
 
 
siCD151 + Doxorubicin (↓ IC50) 
CD151
nucleus
Decreased
Tumor growth
Migration
Invasion
Metastasis
Tumor growth
Migration
Invasion
Metastasis
α-β integrins
signaling
growth factor receptor
complex
Doxorubicin (IC50)
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Gene Function Mechanism affecting 
sensitivity 
Reference 
 
 
 
NPTN 
(Neuroplastin) 
 
Probable homophilic 
and heterophilic cell 
adhesion molecule. In 
cancer context it 
activates the FGFR 
signaling pathway, 
promoting neo-
angiogenesis and 
metastasis. 
 
 
 
FGFR inhibition 
synergizes with 
Doxorubicin treatment 
leading to increased 
sensitivity (lower IC50 
value for Doxorubicin 
treatment). 
 
Beesley PW et al, J 
Neurochem 2014  
Roidl A et al, Clin 
Cancer Res 2009  
Byron SA et al, Int J 
Gynecol Cancer 2012 
 
 
 
 
siNPTN + Doxorubicin (↓ IC50)
NPTN
nucleus
signaling
Decreased
Neo-angiogenesis
Metastasis
Neo-angiogenesis
Metastasis
FGFR
Doxorubicin (IC50)
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Table 7. Potential mechanism of action following genes silencing that confers resistance to 
doxorubicin treatment. 
Gene Function Mechanism affecting 
resistance 
Reference 
 
 
 
 
 
 
TP53 
(Tumor Protein 
p53) 
 
 
 
A key tumor suppressor 
that acts in many tumor 
types, inducing growth 
arrest, senescence or 
apoptosis depending on 
the physiological 
circumstances and cell 
type. Involved in cell 
cycle regulation as a 
trans-activator that acts 
to negatively regulate 
cell division by 
controlling genes 
required for this 
process. 
 
Loss of p53 or mutation 
augments resistance to 
Doxorubicin (Dox) 
mediated apoptotic and 
non-apoptotic death. 
Several p53-dependent 
cell death inducing 
routes upon Dox 
treatment include: i) the 
DNA damage response 
(DDR) pathway, ii) the 
mitochondrial 
cyclophilin D/p53 
complex, iii) p53 assisted 
TGF-β/Smad3 apoptosis 
induction. Consequently 
cells develop increased 
resistance to Dox 
requiring higher IC50 
values of the drug. 
 
 
 
Lu J-H et al, Mol Cell 
Biochem 2014  
Aas T et al, Nat Med 
1996  
Sun Y et al, Am J 
Cancer Res 2015  
Wang S et al, J Biol 
Chem 2004  
O’Connor MJ, Mol 
Cell 2015 
Negrini S et al, Nat 
Rev Mol Cell Biol. 
2010  
Kastenhuber ER, 
Lowe SW, Cell 2017  
 
 
 
 
Gene Function Mechanism affecting 
resistance 
Reference 
 
 
 
 
 
 
 
 
 
 
 
DNA binding protein 
 
Evidence indicates that 
doxorubicin forms a 
complex with the DNA 
by intercalation of its 
planar rings between 
 
 
 
 
 
 
siTP53 + Doxorubicin (↑ IC50)
TGFBR
nucleus
signaling
Decreased
Cell death
(eg apoptosis)
Cell death
(eg apoptosis)
p53
Smad
mitochondrium
Genotoxic stress/
DDR activation
cyclophilin D
Doxorubicin (IC50)
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CTCF 
(11-zinc finger 
protein or 
CCCTC-binding 
factor) 
responsible for insulator 
function, nuclear 
architecture and 
transcriptional control, 
which probably acts by 
recruiting epigenetic 
chromatin modifiers.  
nucleotide base pairs. 
This intercalation 
generates bidirectional 
torsional stress on the 
DNA helix, which along 
with the Topoisomerase 2 
inhibitory effect of 
Doxorubicin, leads 
eventually to DNA 
double strand breaks. The 
stress is possibly relieved 
upon removal of CTCF 
stable boundaries, thus 
requiring higher 
Doxorubicin (IC50 
values) to exert a similar 
stress induced DNA 
damage and cell death. 
 
Yang F et al, 
Biochim Biophys 
Acta 2014  
O’Connor MJ, Mol 
Cell 2015  
Canela A et al, Cell 
2017  
 
 
 
 
 
 
Gene Function Mechanism affecting 
resistance 
Reference 
 
 
 
CCND3 
(cyclin D3) 
 
 
Member of the highly 
conserved cyclin D 
family, regulating cell 
cycle progression. It 
also activates Caspase 
2, triggering apoptosis. 
 
CCND3 silencing results 
in loss of sensitizing 
cells to apoptosis 
through inability to 
activate Caspase 2. In 
turn, higher Doxorubicin 
IC50 values are required 
to bypass the acquired 
resistance to this drug. 
 
 
 
 
Mendelsohn AR et al, 
PNAS 2002  
siCTCF + Doxorubicin (↑ IC50)
CCTCF
Doxorubicin (IC50)
Doxorubicin
torsion stressTAD TAD
DNA double strand break
torsion stress accumulation
torsion stress dissipation
TAD: Topological Associated Domain (loop)
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siCCND3 + Doxorubicin (↑ IC50)
nucleus
Decreased
Apoptosis
Apoptosis
CCND3
Caspase 2
Doxorubicin (IC50)
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Gene Function Mechanism affecting 
resistance 
Reference 
 
 
 
ARHGDIB  
(Rho GDP 
dissociation 
inhibitor beta) 
 
 
Regulates the 
GDP/GTP exchange 
reaction of the Rho 
proteins by inhibiting 
the dissociation of GDP 
from them, and the 
subsequent binding of 
GTP.  
 
 
Aberrantly activated 
Rho proteins promote 
many “hallmarks” of 
cancer. Silencing of 
ARHGDIB facilitates 
activation of Rho 
proteins that mediate 
increased resistance to 
Doxorubicin treatment 
(higher IC50 values). 
 
Rickardson L et al, 
Br J Cancer 2005  
Sahai E, Marshall CJ, 
Nat Rev Cancer 2002  
Porter AP et al, Small 
G Pases 2016  
 
 
 
 
 
siARHGDIB + Doxorubicin (↑ IC50)
GTP
Enhanced
Tumor
growth 
Control over
Tumor
growth
ARHGDIB
GDP
Rho
inactive
active
inactive
active
Doxorubicin (IC50)
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Gene Function Mechanism affecting 
resistance 
Reference 
 
 
 
ZCCHC7 
(zinc finger 
CCHC-type 
containing 7) 
 
 
 
Possibly involved in 
deadenylation-dependent 
mRNA decay. 
 
ZCCHC7 down-
regulation in Acute 
lymphoblastic leukemia 
(ALL) is associated with 
relapse and poor 
survival. Its silencing in 
breast cancer is 
associated with increased 
cell proliferation. 
Therefore higher IC50 
Doxorubicin values are 
required to arrest tumor 
cell growth. 
 
 
 
Nunez-Enriquez JC 
et al, Arch Med Res 
2016  
Rangel R et al, 
Cancer Res 2017  
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siZCCHC7 + Doxorubicin (↑ IC50)
nucleus
Decreased
Cell growth
Cell growth
ZCCHC7
Doxorubicin (IC50)
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